WO2008071972A1 - Novel compounds and their effects on feeding behaviour - Google Patents

Novel compounds and their effects on feeding behaviour Download PDF

Info

Publication number
WO2008071972A1
WO2008071972A1 PCT/GB2007/004779 GB2007004779W WO2008071972A1 WO 2008071972 A1 WO2008071972 A1 WO 2008071972A1 GB 2007004779 W GB2007004779 W GB 2007004779W WO 2008071972 A1 WO2008071972 A1 WO 2008071972A1
Authority
WO
WIPO (PCT)
Prior art keywords
giu
asn
ala
leu
lys
Prior art date
Application number
PCT/GB2007/004779
Other languages
French (fr)
Inventor
Stephen Robert Bloom
Original Assignee
Imperial Innovations Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0624868.6A external-priority patent/GB0624868D0/en
Priority claimed from GB0625667A external-priority patent/GB0625667D0/en
Priority claimed from GB0700897A external-priority patent/GB0700897D0/en
Priority to MX2009006348A priority Critical patent/MX2009006348A/en
Priority to BRPI0721093-0A priority patent/BRPI0721093A2/en
Priority to NZ578213A priority patent/NZ578213A/en
Application filed by Imperial Innovations Limited filed Critical Imperial Innovations Limited
Priority to AU2007331257A priority patent/AU2007331257B2/en
Priority to RU2009126634/04A priority patent/RU2492183C2/en
Priority to UAA200907137A priority patent/UA102370C2/en
Priority to CN200780044820.9A priority patent/CN101578107B/en
Priority to JP2009540858A priority patent/JP5669395B2/en
Priority to CA002672406A priority patent/CA2672406A1/en
Publication of WO2008071972A1 publication Critical patent/WO2008071972A1/en
Priority to IL199247A priority patent/IL199247A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This application relates to the use of agents to control appetite, feeding, food intake, energy expenditure and calorie intake, treat excess weight, obesity and to prevent and treat the comorbidities of obesity.
  • WHO World Health Organization
  • obesity is complex and multi-factorial. Increasing evidence suggests that obesity is not a simple problem of self-control but is a complex disorder involving appetite regulation and energy metabolism. In addition, obesity is associated with a variety of conditions associated with increased morbidity and mortality in a population. Although the etiology of obesity is not definitively established, genetic, metabolic, biochemical, cultural and psychosocial factors are believed to contribute. In general, obesity has been described as a condition in which excess body fat puts an individual at a health risk.
  • a weight loss of 10% of the initial body weight in both overweight and obese adults has been associated with a decrease in risk factors such as hypertension, hyperlipidemia, and hyperglycemia.
  • risk factors such as hypertension, hyperlipidemia, and hyperglycemia.
  • Pharmacotherapy is available; several weight loss drugs have been approved by the US Food and Drug Administration that can be used as part of a comprehensive weight loss program. However, many of these drugs have serious adverse side effects.
  • An example of a widely used appetite suppressant is sibutramine (reviewed by McNeely, W et al., Drugs, 1998, 56(6), 1093-1124).
  • Sibutramine's primary and secondary metabolites are pharmacologically active and they are thought to induce enhancement of satiety and thermogenesis by inhibiting serotonin and noradrenaline reuptake.
  • weight loss surgery is an option in carefully selected patients with clinically severe obesity.
  • these treatments are high-risk, and suitable for use in only a limited number of patients (Wolfe and Morton, JAMA, 2005, 294,1960-1963). It is not only obese subjects who wish to lose weight. People with weight within the recommended range, for example, in the upper part of the recommended range, may wish to reduce their weight, to bring it closer to the ideal weight.
  • Oxyntomodulin (hereafter oxm) is a 37 amino acid peptide member of the glucagon superfamily (Sherwood et al, Endocrine Reviews, 2000, 21(6): 619-670) comprising the entire 29 amino acid sequence of glucagon, with an eight amino acid carboxy terminal extension, resulting from the tissue-specific processing of the pre-pro-glucagon precursor in the brain and gut (Hoist, Ann Rev Physiol, 1997, 59:257-271).
  • WO 03/022304 discloses the use of oxm in its native form and analogues thereof as a medicament for use in control of appetite, feeding, food intake, energy expenditure and calorie intake, particularly in the field of obesity. Studies in humans have shown that intravenously infused oxm is an effective appetite suppressant (Cohen et al, J. Clin. Endocrinol Metab, 2003, 88(10): 4696-4701).
  • Peptides are widely used in medical practice, although when native peptides or analogues thereof are used in therapy it is generally found that they have a high clearance rate and/or are sensitive to degradation. In particular, a high clearance or rapid degradation of a therapeutic agent is inconvenient in cases where it is desired to maintain a high blood level over a prolonged period of time since repeat administrations will then be necessary, decreasing patient compliance and increasing the cost of the therapy.
  • oxm analogues novel peptide analogues of oxm in which one or more amino acids or parts of the oxm sequence have been replaced by one or more particular substituent amino acids or sequences. Accordingly, the invention provides a peptide comprising the amino acid sequence:
  • Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
  • the invention provides a peptide comprising the amino acid sequence:
  • Xaal is Hisl or D-Hisl
  • Xaa2 is Ser2 or Ala2
  • Xaa3 is Gln3 or Asp3
  • Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
  • Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
  • Xaal5 Xaal ⁇ Xaal7 Xaal ⁇ Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is Aspl5 Serl ⁇ Argl7 Argl8 Alal9 Gln20 Asp21 Phe22 Val23 Gln24, then Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is not Met27 Asn28 Thr29 Lys30 Arg31 Asn32.
  • the peptides of the invention are potent and long-lasting appetite suppressants.
  • Figure 1 discloses 355 specific peptide sequences falling within the scope of the invention.
  • Figures 2 to 41 show the results of Examples 1 to 19.
  • Figure 2 relates to Example 1.
  • Figure 3 relates to Example 2.
  • Figure 4 relates to Example 3 (PEPTIDE NO: 94).
  • Figure 5 relates to Example 3 (PEPTIDE NO: 82).
  • Figure 6 relates to Example 3 (PEPTIDE NO: 58).
  • Figure 7 relates to Example 3 (PEPTIDE NO: 52).
  • Figure 8 relates to Example 4 (PEPTIDE NO: 164).
  • Figure 9 relates to Example 4 (PEPTIDE NO: 167).
  • Figure 10 relates to Example 5 (PEPTIDE NO: 100).
  • Figure 1 1 relates to Example 5 (PEPTIDE NO: 148).
  • Figure 12 relates to Example 6 (PEPTIDE NO: 60).
  • Figure 13 relates to Example 6 (PEPTIDE NO: 178).
  • Figure 14 relates to Example 7 (PEPTIDE NO: 155).
  • Figure 15 relates to Example 8 (PEPTIDE NO: 142).
  • Figure 16 relates to Example 8 (PEPTIDE NO: 172).
  • Figure 17 relates to Example 8 (PEPTIDE NO: 184).
  • Figure 19 relates to Example 9 (PEPTIDE NO: 108).
  • Figure 20 relates to Example 9 (PEPTIDE NO: 195).
  • Figure 21 relates to Example 9 (PEPTIDE NO: 136).
  • Figure 22 relates to Example 10 (PEPTIDE NO: 142).
  • Figure 23 relates to Example 10 (PEPTIDE NO: 22).
  • Figure 24 relates to Example 10 (PEPTIDE NO: 153).
  • Figure 25 relates to Example 10 (PEPTIDE NO: 199).
  • Figure 26 relates to Example 11 (PEPTIDE NO: 210).
  • Figure 27 relates to Example 11 (PEPTIDE NO: 211).
  • Figure 28 relates to Example 11 (PEPTIDE NO: 213).
  • Figure 29 relates to Example 11 (PEPTIDE NO: 214).
  • Figure 30 relates to Example 12 (PEPTIDE NO: 201).
  • Figure 31 relates to Example 12 (PEPTIDE NO: 202).
  • Figure 32 relates to Example 13 (PEPTIDE NO: 203).
  • Figure 33 relates to Example 14 (PEPTIDE NO: 204).
  • Figure 34 relates to Example 14 (PEPTIDE NO: 205).
  • Figure 35 relates to Example 15 (PEPTIDE NO: 206).
  • Figure 36 relates to Example 15 (PEPTIDE NO: 207).
  • Figure 37 relates to Example 15 (PEPTIDE NO: 209).
  • Figure 39 relates to Example 17 (PEPTIDE NO: 216).
  • Figure 40 relates to Example 18 (PEPTIDE NO: 355).
  • Figure 41 relates to Example 19 (PEPTIDE NO: 130).
  • Animal Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds.
  • mammal includes both human and non-human mammals.
  • subject includes both human and non-human subjects, including veterinary subjects.
  • appetite A natural desire, or longing for food.
  • appetite is measured by a survey to assess the desire for food. Increased appetite generally leads to increased feeding behavior.
  • appetite suppressants Compounds that decrease the desire for food.
  • Commercially available appetite suppressants include, but are not limited to, amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine fenfluramine, dexfenfluramine, sibutramine, rimonabant and fluoxetine.
  • Body Mass Index A mathematical formula for measuring body mass, also sometimes called Quetelet's Index. BMI is calculated by dividing weight (in kg) by height 2 (in meters 2 ).
  • the recommended classifications for BMI in humans adopted by the Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults, and endorsed by leading organizations of health professionals, are as follows: Underweight ⁇ 18.5 kg/m 2 ; Normal weight 18.5-24.9 kg/m 2 ; Overweight 25-29.9 kg/m 2 ; Obesity (Class 1) 30-34.9 kg/m 2 ; Obesity (Class 2) 35-39.9 kg/m 2 ; Extreme obesity (Class 3) >40 kg/m 2 (Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults, The North American Association for the Study of Obesity (NAASO) and the
  • a BMI of greater than 25 kg/m 2 can be used to identify a subject in need of a treatment for excess weight or obesity.
  • Ideal body weight will vary among species and individuals based on height, body build, bone structure, and sex.
  • Conservative substitutions The replacement of an amino acid residue by another similar residue in a polypeptide. Typical but not limiting conservative substitutions are the replacements, for one another, among the aliphatic amino acids Ala, VaI, Leu and He; interchange of Ser and Thr containing hydroxy residues, interchange of the acidic residues Asp and GIu, interchange between the amide-containing residues Asn and GIn, interchange of the basic residues Lys and Arg, interchange of the aromatic residues Phe and Tyr, and interchange of the small-sized amino acids Ala, Ser, Thr, Met and GIy. Additional conservative substitutions include the replacement of an amino acid by another of similar spatial or steric configuration, for example the interchange of Asn for Asp, or GIn for GIu.
  • Non-conservative substitutions The replacement, in a polypeptide, of an amino acid residue by another residue which is not biologically similar. For example, the replacement of an amino acid residue with another residue that has a substantially different charge, a substantially different hydrophobicity or a substantially different spatial or steric configuration.
  • alternative amino acid encompasses alternative amino acids that are the result of both conservative and non-conservative substitutions.
  • rare amino acids for example, canavanine, ornithine and 5-hydroxytryptophane
  • artificial amino acids that is to say amino acids not normally found in vivo, for example t-butylglycine
  • Any chiral form of an amino acid may be used.
  • Diabetes A failure of cells to transport endogenous glucose across their membranes either because of an endogenous deficiency of insulin and/or a defect in insulin sensitivity. Diabetes is a chronic syndrome of impaired carbohydrate, protein, and fat metabolism owing to insufficient secretion of insulin or to target tissue insulin resistance. It occurs in two major forms: insulin-dependent diabetes mellitus (IDDM, type I) and non-insulin dependent diabetes mellitus (NIDDM, type II) which differ in etiology, pathology, genetics, age of onset, and treatment.
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin dependent diabetes mellitus
  • Diabetes type I or insulin dependent diabetes mellitus (DDDM) is caused by the destruction of pancreatic ⁇ cells, which results in insufficient levels of endogenous insulin.
  • Diabetes type II or non-insulin dependent diabetes, results from a defect in both the body's sensitivity to insulin, and a relative deficiency in insulin production.
  • Food intake The amount of food consumed by an individual subject. Food intake can be measured by volume or by weight. For example, food intake may be the total amount of food consumed by an individual subject. Or, food intake may be the amount of proteins, fat, carbohydrates, cholesterol, vitamins, minerals, or any other food component, of the individual subject. "Protein intake” refers to the amount of protein consumed by an individual. Similarly, “fat intake,” “carbohydrate intake,” “cholesterol intake,” “vitamin intake,” and “mineral intake” refer to the amount of fat, carbohydrates, cholesterol, vitamins, or minerals consumed by an individual subject respectively.
  • Normal Daily Diet The average food intake for an individual of a given species.
  • a normal daily diet can be expressed in terms of caloric intake, protein intake, carbohydrate intake, and/or fat intake.
  • a normal daily diet in humans generally comprises the following: about
  • a normal daily diet in humans generally includes about 12 g to about 45 g of protein, about 120 g to about 61O g of carbohydrate, and about 11 g to about 90 g of fat.
  • a low calorie diet would be no more than about 85%, and preferably no more than about 70%, of the normal caloric intake of a human individual.
  • the caloric and nutrient requirements vary depending on the species and size of the animal. For example, in cats, the total caloric intake per pound, as well as the percent distribution of protein, carbohydrate and fat varies with the age of the cat and the reproductive state.
  • a general guideline for cats is 40 cal/lb/day (18.2 cal/kg/day). About 30% to about 40% should be protein, about 7% to about 10% should be from carbohydrate, and about 50% to about 62.5% should be derived from fat intake.
  • One of skill in the art can readily identify the normal daily diet of an individual of any species.
  • Obesity A condition in which excess body fat may put a person at health risk (see Barlow and Dietz, Pediatrics 102:E29, 1998; National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Obes. Res. 6 (suppl. 2):51S-209S, 1998). Excess body fat is a result of an imbalance of energy intake and energy expenditure. For example, the Body Mass Index (BMI) may be used to assess obesity. In one commonly used convention, a BMI of 25.0 kg/m 2 to 29.9 kg/m 2 is overweight, while a BMI of 30 kg/m 2 or greater is obese.
  • BMI Body Mass Index
  • Overweight An individual who weighs more than their ideal body weight.
  • An overweight individual can be obese, but is not necessarily obese.
  • an overweight individual is any individual who desires to decrease their weight.
  • an overweight individual is an individual with a BMI of 25.0 kg/m 2 to 29.9 kg/m 2 .
  • Pegylation the process of reacting a poly(alkylene glycol), preferably an activated poly(alkylene glycol) to form a covalent bond.
  • a facilitator may be used, for example an amino acid, e.g. lysine.
  • Peripheral Administration Administration outside of the central nervous system. Peripheral administration does not include direct administration to the brain. Peripheral administration includes, but is not limited to intravascular, intramuscular, subcutaneous, inhalation, oral, rectal, transdermal, buccal, sub-lingual or intra-nasal administration
  • polypeptide fragment refers to a portion of a polypeptide, for example such a fragment which exhibits at least one useful sequence in binding a receptor.
  • functional fragments of a polypeptide refers to all fragments of a polypeptide that retain an activity of the polypeptide.
  • Biologically functional peptides can also include fusion proteins, in which the peptide of interest is fused to another peptide(s).
  • Therapeutically effective amount A dose sufficient to prevent advancement, or to cause regression of a disorder, or which is capable of relieving a sign or symptom of a disorder, or which is capable of achieving a desired result.
  • a therapeutically effective amount of a compound of the invention is an amount sufficient to inhibit or halt weight gain, or an amount sufficient to decrease appetite, or an amount sufficient to reduce caloric intake or food intake or increase energy expenditure, or an amount sufficient to reduce weight, or to reduce the risk of mortality or morbidity from conditions associated with the disorder.
  • oxm analogues of the invention are effective appetite suppressants and/or have a more sustained effect than native oxm on food intake, and/or have a more potent effect than native oxm on food intake.
  • the peptides of the invention also have a longer half-life or clearance time or improved resistance to degradation as compared with oxm. Increased duration of appetite suppression can be particularly important to avoid the effect known as "escape".
  • a short duration appetite suppressant may reduce appetite for the time covered by one meal and, in that meal, the subject typically eats less food. If, however, the appetite suppressant has a short half-life or rapid clearance time or is then metabolized or otherwise removed from the circulation of the subject, then by the time of the next mealtime, the subject can regain its "normal" appetite. In view of the subject having eaten a small meal at the previous mealtime, the subject may in fact have an increased appetite by the time of the subsequent meal.
  • the subject satisfies that appetite, it is possible for the food intake over the two meals, in total, to be no lower than the food intake would have been without the appetite suppressant. That is to say that the subject may have "escaped” from the effects of the appetite suppressant. "Escape” can be reduced by using additional doses of appetite suppressant, or by using an appetite suppressant with a longer duration of action. If the subject has a reduced appetite for longer, then the degree to which it can make up the missed food from one meal in the next meal is reduced as there is a practical limit to the total capacity for food in a particular meal. Repeated or continuous administration of a compound over a period of time, for example over a period of days or weeks, will lead to extended appetite suppression and reduced potential for escape from the effects of the appetite suppression.
  • the improved activity and/or duration of action of the oxm analogues as compared with oxm offers various advantages. For example, effective suppression of appetite at lower dosages will be permitted (with the lower dosage and/or lower peak levels, offering the prospect of reduced side effects (including nausea) and reduction in the cost of treatment), or usage at relatively high dosages will be better tolerated by the patient enabling quicker and/or greater weight loss.
  • Certain of the compounds of the invention used in the Examples herein exhibit a pattern of appetite suppression indicative of a 'flatter blood curve', that is to say they have improved pharmacokinetids, by virture of displaying either or both of (i) a more gradual onset of the appetite suppressant activity than oxm and thereby potentially avoid an initial sharp peak (which may be associated with nausea); and (ii) a potentially longer duration of action.
  • the compounds have improved storage characteristics and are amenable to large scale synthesis, for example some compounds of the invention do not contain sequence motifs associated with the formation of aspartimide species, and/or are less prone to reduced stability.
  • the invention provides a peptide wherein
  • Xaal5 Xaal6 Xaal7 Xaal ⁇ Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
  • a peptide of the invention is one wherein
  • Xaal5 Xaal ⁇ Xaal7 Xaal ⁇ Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is: Glul5 Glnl ⁇ Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24,
  • Glul5 Glul ⁇ Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24 Glul5 Glnl ⁇ Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glul ⁇ Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnl ⁇ Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, or Glul5 Glul ⁇ Glul7 Leul 8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24.
  • a peptide of the invention is one wherein Xaal5 Xaal ⁇ Xaal7 Xaal8 Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
  • a peptide of the invention comprises Xaal Xaa2 Xaa3 selected from the group consisting of:
  • a peptide of the invention is one wherein
  • Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is: Lys27 Asn28 Ala29 Gly30 Pro31 Ser32,
  • a peptide of the invention is one wherein
  • Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
  • a peptide of the invention is one wherein Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
  • the peptide of the invention may have an amino acid sequence selected from the group comprising:
  • Tyr Phe lie GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 35)
  • Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 87) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu lie VaI Lys Tyr Phe Leu GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 88) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu lie VaI
  • Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 141) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 142) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
  • the peptide of the invention may have the amino acid sequence
  • the peptide of the invention has an extension moiety -A-B-C at the C-terminus. Accordingly, the peptide of the invention may have an additional extension moiety of sequence -A-B-C, wherein:
  • A is absent or 1, 2, 3 or 4 Ala residues or 1, 2, 3 or 4 GIu residues B is absent or 1 , 2, 3 or 4 Ala residues or 1 , 2, 3 or 4 GIu residues provided that A and B do not both comprise Ala residues, and that A and B do not both comprise GIu residues; and
  • C is Lys, or Lys with an acid selected from capric acid, lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid, attached via its -COOH group to the -NH 2 group of the Lys side chain by means of a peptide bond.
  • groups A or B or both A and B are absent.
  • A is GIu and B is Ala.
  • A is one GIu residue
  • B is one Ala residue.
  • C is a Lys residue without substitution.
  • C is a Lys residue with a fatty acid attached via its -COOH group to the - NH2 group of the Lys side chain by means of a peptide bond.
  • the fatty acid may be selected from
  • the C-terminal extension moiety -A-B-C is: Lys38,
  • the arachidoyl group is also known as the icosanoyl group.
  • Exemplary compounds comprising the C-termainal extension moiety -A-B-C may be selected from the group comprising:
  • Lys-stearoyl (SEQ ID NO: 208) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-arachidoyl (SEQ ID NO: 209) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
  • the native bovine oxm sequence (which is the same as the porcine) is as follows:
  • the present invention provides analogues of oxyntomodulin as set out above.
  • the invention further provides peptides that are analogues in which the Lys33 residue of the peptide recited above is replaced with Arg33.
  • the invention provides a peptide of the invention in which residue Asn34 is replaced with Asp34. Certain peptides with Asn34 replaced by Asp34 are shown as PEPTIDES No 215 to 292 in Figure 1. In a further embodiment, the invention provides a peptide in which residue Gln3 or Asp3 is replaced with Glu3. Certain peptides with Glu3 are shown as PEPTIDES No 293 to 355 in Figure 1.
  • the invention further comprises embodiments incorporating the sequences disclosed in the attached examples and/or figures.
  • a compound of the invention may comprise a structure set forth above, modified by well known processes including amidation, glycosylation, carbamylation, alkylation, acylation, for example acetylation, sulfation, phosphorylation, cyclization, lipidization, protein (for example albumin) conjugation and pegylation.
  • Analogues of the invention may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.
  • a compound of the invention may be a fusion protein, whereby the analogue of oxyntomodulin is fused to another protein or polypeptide (the fusion partner) using recombinant methods known in the art.
  • a fusion protein may be synthetically synthesized by any known method.
  • Such a fusion protein comprises the analogue of oxyntomodulin.
  • Any suitable peptide or protein can be used as the fusion partner (e.g., serum albumin, carbonic anhydrase, glutathione-S-transferase, single chain antibodies, antibodies, antibody fragments or thioredoxin, etc.).
  • a compound of the invention could be fused to an immunoglobulin light chain variable domain that has binding specificity for serum albumin, as described in WO 05/118642.
  • Preferred fusion partners will not have an adverse biological activity in vivo.
  • Such fusion proteins may be made by linking the carboxy- terminus of the fusion partner to the amino-terminus of the analogue of oxyntomodulin or vice versa, directly, or via a linker that preferably does not involve the loss of activity of components.
  • the linker may be chemically stable, or labile, for example a cleavable linker may be used to link the analogue of oxyntomodulin to one or more fusion partners.
  • a resulting cleavable fusion protein may be cleaved in vivo such that an active form of a compound of the invention is released.
  • cleavable linkers include, but are not limited to, the linkers D-D-D-D-Y, G-P-R, A-G-G and H-P-F-H-L, which can be cleaved by enterokinase, thrombin, ubiquitin cleaving enzyme and renin, respectively. See, e.g., U.S. Patent No. 6,410,707.
  • a compound of the invention may be a fusion protein, whereby the structure of the compound of the invention is attached to a fusion partner via disulphide bond(s) resulting in a covalent linkage between at least one Cys residue of the compound of the invention, and at least one Cys residue of the fusion partner.
  • a protein When a protein is used as a fusion partner, it is preferably chosen so as not to exhibit undesirable antigenicity. Undesirable antigenicity may be avoided by chosing a protein which is allogenic to the animal to which the compound is to be administered.
  • a compound of the invention may be a physiologically functional derivative of a compound of the invention.
  • physiologically functional derivative is used herein to denote a chemical derivative of a compound of the invention having the same physiological function as the corresponding unmodified compound of the invention.
  • a physiologically functional derivative may be convertible in the body to a compound of the invention.
  • examples of physiologically functional derivatives include esters, amides, and carbamates; preferably esters and amides.
  • esters and amides of the compounds of the invention may comprise a Ci. 6 alkyl-, C 5-10 aryl-, C 5-I0 ar-Ci_ 6 alkyl-, or amino acid-ester or -amide attached at an appropriate site, for example at an acid group.
  • Acyl side chains may be advantageous, for example, by their lipophilic nature causing the moiety to bind with albumin, thus causing a greatly reduced rate of clearance from a subject and so increasing half life and duration of effect.
  • the acyl side chains may be lower acyl, for example Cp C 9 acyl, especially C ⁇ . b acyl, they are preferred to be C 4-40 , in particular C 8 - 25 acyl, especially C ]6 or Qg acyl. Palmitoyl is especially preferred as an acyl side chain as is lauroyl.
  • Acyl side chains may be added at any position on the peptide back bone.
  • an acyl substituent may be attached to an amino acid residue in such a way that a carboxyl group of the acyl substituent forms an amide bond with an amino group of the amino acid residue.
  • an acyl substituent may be attached to an amino acid residue in such a way that an amino group of the acyl substituent forms an amide bond with a carboxyl group of the amino acid residue.
  • the present invention relates to an oxm derivative wherein an acyl substituent is attached to the parent peptide by means of a spacer.
  • the acyl side chain may be added to the lysine residue in advance of the synthesis of the peptide, whereupon its incorporation at the relevant synthetic step will result directly in acylation.
  • This methodology is advantageous if the peptide sequence contains more than one lysine residue as it avoids the necessity of using selective conditions that acylate only the particular lysine of interest.
  • the peptide derivatives have three, more preferably two, and most preferably one acyl side chain substituent. Examples of acyl (and other lipophilic substituents), approaches and specific synthetic methods of attaching such to peptides (with and without the use of spacers) are described in U.S. Patent No. 6,268,343; and U.S. Patent Number 6,458,924.
  • Further examples of saturated fatty acids suitable for acyl derivatisation of compounds of the invention are butyric (butanoic acid): CH 3 (CH 2 ) J COOH; caproic (hexanoic acid):
  • acyl side chains may be added at position 30 and/or position 33 and/or positions 38 to 46 of the peptide back bone.
  • lipidised derivative is relatively labile in the cells and thus facilitates intracellular release of the molecule from the fatty acid moieties.
  • Suitable lipid- containing moieties are hydrophobic substituents with 4 to 26 carbon atoms, preferably 5 to 19 carbon atoms.
  • Suitable lipid groups include, but are not limited to, the following: palmitoyl (Ci 5 H 3I ,), oleoyl (C 15 H 29 ), stearoyl (C 17 H 35 ), cholate; and deoxycholate.
  • Cyclization methods include cyclization through the formation of a disulfide bridge and head- to-tail cyclization using a cyclization resin.
  • Cyclized peptides may have enhanced stability, including increased resistance to enzymatic degradation, as a result of their conformational constraints. Cyclization may in particular be expedient where the uncyclized peptide includes an N-terminal cysteine group.
  • Suitable cyclized peptides include monomelic and dimeric head-to-tail cyclized structures. Cyclized peptides may include one or more additional residues, especially an additional cysteine incorporated for the purpose of formation of a disulfide bond or a side chain incorporated for the purpose of resin-based cyclization.
  • a compound of the invention may be pegylated.
  • Pegylated compounds of the invention may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337).
  • WO 2006/082517 and US 2006/171920 which are incorporated herein by reference, provide examples and associated methods of pegylating peptides and analogues and derivatives thereof.
  • Chemical moieties for derivitization of a compound of the invention may also be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like.
  • a polymer moiety for derivatisation of a compound of the invention may be of any molecular weight, and may be branched or unbranched.
  • the preferred molecular weight of a polyethylene glycol for derivatisation of a compound of the invention is from about 1 kDa to about 100 kDa, the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight.
  • Polymers of other molecular weights may be used, depending on the desired therapeutic profile, for example the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog.
  • the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.
  • Salts and solvates of compounds of the invention that are suitable for use in a medicament are those wherein a counterion or associated solvent is pharmaceutically acceptable.
  • salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of the compounds of the invention and their pharmaceutically acceptable salts or solvates.
  • Suitable salts according to the invention include those formed with organic or inorganic acids or bases.
  • Pharmaceutically acceptable acid addition salts include those formed with hydrochloric, hydrobromic, sulphuric, nitric, citric, tartaric, acetic, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, succinic, perchloric, fumaric, maleic, glycollic, lactic, salicylic, oxaloacetic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic, and isethionic acids.
  • compositions of the invention include ammonium salts, alkali metal salts, for example potassium and sodium salts, alkaline earth metal salts, for example calcium and magnesium salts, and salts with organic bases, for example dicyclohexylamine and N-methyl- D-glucomine.
  • Peptides of the invention may be made by any suitable technique for making peptides, including but not limited to conventional methodology, for example, synthesis from individual amino acids, especially step-wise synthesis using an automatic peptide synthesizer; modification of native peptides; or recombinant manufacturing techniques.
  • the invention provides a pharmaceutical composition comprising a peptide according to the invention and one or more pharmaceutically acceptable carriers.
  • the invention also provides a pharmaceutical composition for use in the control of appetite, feeding, food intake, energy expenditure and calorie intake, the composition comprising an effective amount of a compound according to the invention. More particularly, the invention provides a pharmaceutical composition for use in the treatment of obesity, for use in the treatment of eating disorders, or for use in the treatment of diabetes or a symptom of diabetes, or for use in the treatment or prevention of comorbidities associated with obesity or excess weight.
  • the invention provides a method of of treating or preventing obesity or diabetes or another co-morbitity of obesity in a subject in need thereof comprising administering to the subject an effective amount of a compound or a pharmaceutical composition according to the invention.
  • the invention also provides a method of reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject in need thereof comprising administering to the subject a peptide or a pharmaceutical composition according to the invention.
  • the invention also provides a method of causing weight loss or preventing weight gain for cosmetic purposes comprising administering to the subject a peptide or a pharmaceutical composition according to the invention.
  • the invention also provides use of a compound according to the invention in the manufacture of a medicament for use in the treatment of a condition selected from obesity, eating disorders, diabetes, heart disease, hypertension, lipid disease, and disorders of intestinal and gastric motor activity and other aspects of gut and intestinal function, for example, water absorption and fluid handling, or pancreatic function including the endocrine pancreas, or disorders of hepato-biliary function, or prevention of cancer.
  • a peptide of the invention for the manufacture of a medicament for the treatment of obesity or diabetes or of a co-morbidity of obesity.
  • the invention provides use of a compound according to the invention in the manufacture of a medicament for use in the control of any one or more of appetite, feeding, food intake, energy expenditure and calorie intake.
  • the invention provides the use of a peptide of the invention for the manufacture of a medicament for reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject.
  • the subject to whom the compound is administered may be overweight, for example, obese.
  • the subject may be diabetic, for example having insulin resistance or glucose intolerance, or both.
  • the subject may have diabetes mellitus, for example, the subject may have Type II diabetes.
  • the subject may be overweight, for example, obese and have diabetes mellitus, for example, Type II diabetes.
  • obesity is a recognized risk factor for increased incidence of complications of general anesthesia. (See e.g., Kopelman, Nature 404:635-43, 2000). In general, obesity reduces life span and carries a serious risk of co-morbidities such as those listed above.
  • Other diseases or disorders associated with obesity are birth defects, maternal obesity being associated with increased incidence of neural tube defects, carpal tunnel syndrome (CTS); chronic venous insufficiency (CVI); daytime sleepiness; deep vein thrombosis (DVT); end stage renal disease (ESRD); gout; heat disorders; impaired immune response; impaired respiratory function; infertility; liver disease; lower back pain; obstetric and gynecologic complications; pancreatititis; as well as abdominal hernias; acanthosis nigricans; endocrine abnormalities; chronic hypoxia and hypercapnia; dermatological effects; elephantitis; gastroesophageal reflux; heel spurs; lower extremity edema; mammegaly which causes considerable problems such as bra strap pain, skin damage, cervical pain, chronic odors and infections in the skin folds under the breasts, etc.; large anterior abdominal wall masses, for example abdominal panniculitis with frequent panniculitis, impeding walking, causing frequent infections, odors
  • the present invention further provides a method for increasing energy expenditure in a subject.
  • the method includes, for example, peripherally administering a therapeutically effective amount of a compound of the invention to the subject, thereby altering energy expenditure. Energy is burned in all physiological processes.
  • the method of the invention involves manipulation of the arcuate circuitry that alter food intake coordinately, and reciprocally alter energy expenditure.
  • Energy expenditure is a result of cellular metabolism, protein synthesis, metabolic rate, and calorie utilization.
  • administration of a compound of the invention may result in increased energy expenditure, and decreased efficiency of calorie utilization.
  • the invention also provides a method for improving a lipid profile in a subject.
  • the invention also provides a method for alleviating a condition or disorder that can be alleviated by reducing nutrient availability.
  • Appetite can be measured by any means known to one of skill in the art.
  • decreased appetite can be assessed by a psychological assessment.
  • administration of a compound of the invention results in a change in perceived hunger, satiety, and/or fullness.
  • Hunger can be assessed by any means known to one of skill in the art.
  • hunger is assessed using psychological assays, such as by an assessment of hunger feelings and sensory perception using a questionnaire, such as, but not limited to, a Visual Analog Score (VAS) questionnaire.
  • hunger is assessed by answering questions relating to desire for food, drink, prospective food consumption, nausea, and perceptions relating to smell or taste.
  • a compound of the invention may be used for weight control and treatment, for example reduction or prevention of obesity, in particular any one or more of the following: preventing and reducing weight gain; inducing and promoting weight loss; and reducing obesity as measured by the Body Mass Index.
  • a compound of the invention may be used in the control of any one or more of appetite, satiety and hunger, in particular any one or more of the following: reducing, suppressing and inhibiting appetite; inducing, increasing, enhancing and promoting satiety and sensations of satiety; and reducing, inhibiting and suppressing hunger and sensations of hunger.
  • a compound of the invention may be used in maintaining any one or more of a desired body weight, a desired Body Mass Index, a desired appearance and good health.
  • a subject may be a subject who desires weight loss, for example female and male subjects who desire a change in their appearance.
  • a subject may desire decreased feelings of hunger, for example the subject may be a person involved in a lengthy task that requires a high level of concentration, for example soldiers on active duty, air traffic controllers, or truck drivers on long distance routes, etc.
  • the present invention may also be used in treating, prevention, ameliorating or alleviating conditions or disorders caused by, complicated by, or aggravated by a relatively high nutrient availability.
  • condition or disorder which can be alleviated by reducing caloric (or nutrient) availability is used herein to denote any condition or disorder in a subject that is either caused by, complicated by, or aggravated by a relatively high nutrient availability, or that can be alleviated by reducing nutrient availability, for example by decreasing food intake.
  • Subjects who are insulin resistant, glucose intolerant, or have any form of diabetes mellitus, for example, type 1 , 2 or gestational diabetes can also benefit from methods in accordance with the present invention.
  • Conditions or disorders associated with increased caloric intake include, but are not limited to, insulin resistance, glucose intolerance, obesity, diabetes, including type 2 diabetes; eating disorders, insulin-resistance syndromes, and Alzheimer's disease.
  • a compound of the invention is preferably used in the treatment of a human.
  • the compounds of the invention will typically be used to treat human subjects they may also be used to treat similar or identical conditions in other vertebrates for example other primates; farm animals for example swine, cattle and poultry; sport animals for example horses; companion animals for example dogs and cats.
  • the invention also provides a peptide of the invention for use as a medicament for the prevention or treatment of obesity.
  • a peptide of the invention for use as a medicament for the prevention or treatment of diabetes or of a co-morbidity of obesity.
  • a peptide of the invention for use as a medicament for reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject.
  • the invention also provides a method of treating or preventing obesity in a subject in need thereof comprising administering to the subject a peptide according to the invention.
  • a method of treating or preventing diabetes or of a co-morbidity of obesity in a subject in need thereof comprising administering to the subject a peptide according to the invention.
  • a method of reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject in need thereof comprising administering to the subject a peptide according to the invention or a pharmaceutical composition according to the invention.
  • compositions While it is possible for the active ingredient to be administered alone, it is preferable for it to be present in a pharmaceutical formulation or composition. Accordingly, the invention provides a pharmaceutical formulation comprising a compound of the invention, or a variant or derivative thereof, or a salt or solvate thereof, as defined above, and a pharmaceutically acceptable excipient.
  • Pharmaceutical compositions of the invention may take the form of a pharmaceutical formulation as described below.
  • the pharmaceutical formulations according to the invention include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, and intraarticular), inhalation (including fine particle dusts or mists which may be generated by means of various types of metered doses, pressurized aerosols, nebulizers or insufflators, and including intranasally or via the lungs), rectal and topical (including dermal, transdermal, transmucosal, buccal, sublingual, and intraocular) administration, although the most suitable route may depend upon, for example, the condition and disorder of the recipient.
  • parenteral including subcutaneous, intradermal, intramuscular, intravenous, and intraarticular
  • inhalation including fine particle dusts or mists which may be generated by means of various types of metered doses, pressurized aerosols, nebulizers or insufflators, and including intranasally or via the lungs
  • rectal and topical including dermal, transdermal
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with a pharmaceutical carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • Various pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang, Y. J. and Hanson, M. A., Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S, 1988.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • the present compounds can, for example, be administered in a form suitable for immediate release or extended release.
  • Immediate release or extended release can be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps.
  • the compounds can be formulated, for administration orally, with delivery agents or carriers that facilitate the transport of therapeutic macromolecules and highly charged compounds across cell membranes, especially in the small intestine.
  • Such delivery agents or carriers may in addition inhibit enzymatic degradation of peptides during passage through the gastrointestinal (GI) tract and/or the formulation may include additional agents that protect against such degradation.
  • the present compounds can also be administered liposomally.
  • compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art.
  • the compounds of the invention can also be delivered through the oral cavity by sublingual and/or buccal administration.
  • Moulded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used.
  • Exemplary compositions include those formulating the present compound(s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG).
  • Such formulations can also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g. Carbopol 934).
  • HPC hydroxy propyl cellulose
  • HPMC hydroxy propyl methyl cellulose
  • SCMC sodium carboxy methyl cellulose
  • maleic anhydride copolymer e.g., Gantrez
  • agents to control release such as polyacrylic copolymer (e.g. Carbopol 934).
  • Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.
  • Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example saline or water-for-injection, immediately prior to use.
  • An aqueous carrier may be, for example, an isotonic buffer solution at a pH of from about 3.0 to about 8.0, preferably at a pH of from about 3.5 to about 7.4, for example from 3.5 to 6.0, for example from 3.5 to about 5.0.
  • Useful buffers include sodium citrate-citric acid and sodium phosphate-phosphoric acid, and sodium acetate/acetic acid buffers.
  • the composition preferably does not include oxidizing agents and other compounds that are known to be deleterious to oxm and oxm agonists.
  • compositions for nasal aerosol or inhalation administration include solutions in saline, which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
  • saline which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
  • a suitable propellant e.g., dichlorodifluoro-methane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit can be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator can be formulated to contain a powder mix of the compound and a suitable powder base, for example lactose or starch.
  • a compound of the invention is administered as an aerosol from a metered dose valve, through an aerosol adapter also known as an actuator.
  • a stabilizer is also included, and/or porous particles for deep lung delivery are included (e.g., see U.S. Patent No. 6,447,743).
  • Intranasal formulations may include delivery agents for reversibly opening the nasal tight junction, thereby increasing drug permeability (e.g., see US Patent Application 10/322,266).
  • Formulations for rectal administration may be presented as a retention enema or a suppository with the usual carriers such as cocoa butter, synthetic glyceride esters or polyethylene glycol. Such carriers are typically solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
  • Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerine or sucrose and acacia.
  • exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).
  • Preferred unit dosage formulations are those containing an effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • sustained-release systems include suitable polymeric materials, for example semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules; suitable hydrophobic materials, for example as an emulsion in an acceptable oil; or ion exchange resins; and sparingly soluble derivatives of the compound of the invention, for example, a sparingly soluble salt.
  • Sustained-release systems may be administered orally; rectally; parenterally; intracistemally; intravaginally; intraperitoneally; topically, for example as a powder, ointment, gel, drop or transdermal patch; bucally; or as an oral or nasal spray.
  • compositions may be in the form of particles comprising one or more of biodegradable polymers, polysaccharide jellifying and/or bioadhesive polymers, amphiphilic polymers, agents capable of modifying the interface properties of the particles of the compound of the invention.
  • biodegradable polymers polysaccharide jellifying and/or bioadhesive polymers, amphiphilic polymers, agents capable of modifying the interface properties of the particles of the compound of the invention.
  • amphiphilic polymers agents capable of modifying the interface properties of the particles of the compound of the invention.
  • agents capable of modifying the interface properties of the particles of the compound of the invention exhibit certain biocompatibility features which allow a controlled release of the active substance. See U.S. Patent No. 5,700,486.
  • a compound of the invention may be delivered by way of a pump (see Langer, Science 249:1527-1533, 1990; Sefton, CRC Crit. Ref. Biomed. Eng.
  • Implantable drug infusion devices are used to provide patients with a constant and long term dosage or infusion of a drug or any other therapeutic agent. Essentially such device may be categorized as either active or passive.
  • a compound of the present invention may be formulated as a depot preparation. Such a long acting depot formulation can be administered by implantation, for example subcutaneously or intramuscularly; or by intramuscular injection.
  • the compounds can be formulated with suitable polymeric or hydrophobic materials, for example as an emulsion in an acceptable oil; or ion exchange resins; or as a sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • a therapeutically effective amount of a compound of the invention may be administered as a single pulse dose, as a bolus dose, or as pulse doses administered over time.
  • a bolus administration of a compound of the invention is provided, followed by a time period wherein a compound of the invention is administered to the subject, followed by a second bolus administration.
  • pulse doses of a compound of the invention are administered during the course of a day, during the course of a week, or during the course of a month.
  • a therapeutically effective amount of a compound of the invention is administered with a therapeutically effective amount of another agent, for example an additional appetite suppressant, a food-intake-reducing, dipetidyl peptidase-FV (DPP-IV) inhibiting, plasma glucose-lowering or plasma lipid-altering agent.
  • an additional appetite suppressant include amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine, fenfluramine, dexfenfluramine, sibutramine, rimonabant, and fluoxetine.
  • DPP-IV inhibitors include Januvia (sitagliptin phosphate), and Galvus (vildagliptin).
  • the compound of the invention can be administered simultaneously with the additional agent, or it may be administered sequentially.
  • the compound of the invention is formulated and administered with an additional agent as a single dose.
  • a therapeutically effective amount of a compound of the invention is administered in combination with a therapeutically effective amount of another agent, for the treatment of diseases other than obesity, for example diabetes, in which specific non limiting examples of an additional therapeutic agent are GLP-I or an analogue thereof, exenatide, and pramlintide.
  • a compound of the invention may be administered whenever the effect, e.g., appetite suppression, decreased food intake, or decreased caloric intake, is desired, or slightly before to whenever the effect is desired, such as, but not limited to about 10 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, about 120 minutes, about 4 hours, about 8 hours, or about 12 hours, before the time the effect is desired.
  • the effect e.g., appetite suppression, decreased food intake, or decreased caloric intake
  • a compound of the invention may be administered in combination with whenever the effect, e.g., appetite suppression, decreased food intake, or decreased caloric intake, is desired, or slightly before to whenever the effect is desired, such as, but not limited to about 10 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, about 120 minutes, about 4 hours, about 8 hours, or about 12 hours, before the time the effect is desired.
  • the effect e.g., appetite suppression, decreased food intake, or decreased caloric intake
  • the therapeutically effective amount of a compound of the invention will be dependent on the molecule utilized, the subject being treated, the severity and type of the affliction, and the manner and route of administration.
  • a therapeutically effective amount of a compound of the invention may vary from about 0.01 ⁇ g per kilogram (kg) body weight to about 1 g per kg body weight, for example about .0.1 ⁇ g to about 5 mg per kg body weight, or about 1 ⁇ g to about 1 mg per kg body weight per day.
  • a compound of the invention may be administered to a subject at 0.5 to 200 picomole (pmol) per kg body weight, or about 20 pmol per kg body weight.
  • a compound of the invention is administered in a dose of about 1 nmol or more, 2 nmol or more, 5 nmol or more, or 10 nmol or more and the dose of the compound of the invention is generally not more than 100 nmol, for example, the dose is 90 nmols or less, 80 nmols or less, 70 nmols or less, 60 nmols or less, 50 nmols or less, 40 nmols or less, 30 nmols or less, 20 nmols or less, or 10 nmols or less.
  • a compound of the invention is administered in a dose of about 100 nmol or more, 200 nmol or more, 300 nmol or more, 400 nmol or more, 500 nmol or more, 600 nmol or more, 700 nmol or more, 800 nmol or more, 900 nmol or more, or
  • the dose of the compound of the invention is generally not more than 10 ⁇ mols, for example, the dose is 9 ⁇ mols or less, 8 ⁇ mols or less, 7 ⁇ mols or less, 6 ⁇ mols or less, 5 ⁇ mols or less, 4 ⁇ mols or less, 3 ⁇ mols or less, 2 ⁇ mols or less, 1 ⁇ mol or less.
  • a dosage range may comprise any combination of any of the specified lower dose limits with any of the specified upper dose limits.
  • examples of non-limiting dose ranges of compounds of the invention are within the range of from 1 nmol to 1 ⁇ mol, from 1 to 900 nmols, or from 1 to 800 nmols.
  • the dose may be from 1 nmol to 100 nmol, from
  • the dose may be from 100 nmol to 10 ⁇ mol, from 200 nmol to 5 ⁇ mols, or from 500 nmols to 2 ⁇ mols.
  • from about 0.5 to about 50 nmol of a compound of the invention is administered, for example about 1 to about 20 nmol, for example, about 2 nmol is administered as a subcutaneous injection.
  • the exact dose is readily determined by one of skill in the art based on the potency of the specific compound utilized, the age, weight, sex and physiological condition of the subject.
  • a compound of the invention is administered to a subject in a dose of about 1 ⁇ g to about 2 mg per dose, about once, about twice, about three times, or about four times per day.
  • a therapeutically effective amount of a compound of the invention may vary from about 0.01 ⁇ g per kilogram (kg) body weight to about 1 g per kg body weight, for example about 0.1 ⁇ g to about 5 mg per kg body weight, or about 5 ⁇ g to about 1 mg per kg body weight per day.
  • a compound of the invention may be administered to a subject at 2.25 to 900 ng per kg body weight, or about 90 ng per kg body weight.
  • a compound of the invention is administered in a dose of about 4.5 ⁇ g or more, 9 ⁇ g or more, 22.5 ⁇ g or more, or 45 ⁇ g or more and the dose of the compound of the invention is generally not more than 450 ⁇ g, for example, the dose is 405 ⁇ g or less, 360 ⁇ g or less, 315 ⁇ g or less, 270 ⁇ g or less, 225 ⁇ g or less, 180 ⁇ g or less, 135 ⁇ g or less, 90 ⁇ g or less, or 45 ⁇ g or less.
  • Suitable doses of compounds of the invention also include those that result in a reduction in calorie intake, food intake, or appetite, or increase in energy expenditure that is equivalent to the reduction in calorie intake, food intake, or appetite, or to increase the energy expenditure, caused by levels of oxm that have been observed in man.
  • Examples of doses include, but are not limited to doses that produce the effect demonstrated when the serum levels of oxm are from about 800 pM to about 1300 pM, or from about 900 pM to about 1000 pM, or about 950 pM.
  • the compounds of the invention have been found to be more active and/or longer-lasting than native oxyntomodulin as used in human studies to date (Cohen et al (2003) and Wynne et al. (2005) Diabetes 54(Aug), 2390-2395).
  • the dosage required for a compound of the invention may be somewhat lower than that required for native oxyntomodulin.
  • the dosages of peptides of the invention required to observe an effect in humans can be expected to be a lower, for example 2.5 times, 200 times, 400 times, and 1-4000 times lower than the dose of native oxyntomodulin.
  • the magnitude of the potency of the peptides of the invention in comparison to the native oxyntomodulin peptide may also allow the frequency of administration a compound of the invention to be lower than that required for native oxyntomodulin.
  • mice received two saline injections at least two days apart in order to further acclimatize to the procedure on the study days. It was found in rats that minimising the number of injections provided an optimal response, and so acclimatization injections were not used.
  • IP injections were administered to mice via a 0.5 ml syringe with a 29-gauge needle (maximum injection volume 0.1 ml). The maximum volume administered IP was 0.1 ml.
  • SC injections were administered to rats via a 0.5 ml syringe with a 29-gauge needle (maximum injection volume 0.2 ml), in a volume of 0.1 ml if administered to the thigh skin, or 0.2 ml if administered to the neck scruff.
  • Peptides were produced by solid phase step-wise synthesis (SPSS) using the Fmoc N-terminal protection strategy. Chain assembly was performed on Applied Biosystems 431, 433 or Pioneer automated synthesisers. Solid phase resins were used with factory pre-loaded C terminal amino acid or with an amide linker as appropriate. The following side-chain protecting groups were used: Asn(Trt), Gln(Trt), Cys(Trt), His(Trt), Asp(tBu), Glu(tBu),
  • Peptides were dissolved in de-ionized water, with addition of acetic acid where necessary. Peptide solutions were clarified by centrifugation or filtration (Whatman GD/X syringe filter) prior to analysis and purification.
  • Purified peptides were freeze-dried in pharmaceutical grade glass vials (Adelphi Vials) and closed under vacuum.
  • Derivatised side chains Peptides having side chains derivatised with an acyl or alkyl group were prepared by standard methods.
  • Derivatised polypeptides should be fully dissolved before administration. In order to achieve solubility it may be necessary to dissolve the polypeptides in a small amount of dilute alkali (for example, 50 ⁇ l 0.01 NaOH) and then dilute the dissolved peptide in saline.
  • dilute alkali for example, 50 ⁇ l 0.01 NaOH
  • Example 1 (comparative example).
  • the feeding effect of native oxyntomodulin (human) was investigated by intraperitoneal injection of 1400 nmoles/kg to groups of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 2. Due to the relatively low activity of native oxyntomodulin, a high dose was given. Less significant results are observed with lower doses.
  • the analogues were administered at a dose of 10 (PEPTIDE NO: 178 [SEQ ID NO:178]) and 10 (PEPTIDE NO: 82 [SEQ ID NO:82]; PEPTIDE NO: 58 [SEQ ID NO:58]; and PEPTIDE NO: 52 [SEQ ID NO:52]) nmoles/kg by subcutaneous injection to groups of fasted rats.
  • a further group was administered saline (control).
  • Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 4 to 7.
  • the analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control.
  • the food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
  • Example 4 The feeding effects of the following analogues of oxyntomodulin were investigated:
  • the food intake suppression continues for the whole 48 (PEPTIDE NO: 164 [SEQ ID NO: 164]) and 32 (PEPTIDE NO: 167 [SEQ ID NO: 167]) hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 24 hours (PEPTIDE NO: 164 [SEQ ID NO: 164]) or 8 hours (PEPTIDE NO: 167 [SEQ ID NO: 167]). It is also lower than in the control group treated with native oxyntomodulin.
  • Example 6 The feeding effects of the following analogues of oxyntomodulin were investigated:
  • PEPTIDE NO: 60 [SEQ ID NO:60]; and PEPTIDE NO: 94 [SEQ ID NO:94].
  • the analogues were administered at a dose of 100 and 5 nmoles/kg respectively, by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 12 and 13.
  • the analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
  • Example 8 The feeding effects of the following analogues of oxyntomodulin were investigated:
  • PEPTIDE NO: 142 [SEQ ID NO: 142]; PEPTIDE NO: 184 [SEQ ID NO: 184]; and PEPTIDE NO: 172 [SEQ ID NO: 172].
  • the analogues were administered at a dose of 3 nmoles/kg by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 15 to 17.
  • the analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
  • the feeding effects of the following analogues of oxyntomodulin were investigated: PEPTIDE NO: 4 [SEQ ID NO:4]; PEPTIDE NO: 195 [SEQ ID NO:195]; PEPTIDE NO: 136 [SEQ ID NO:136]; and PEPTIDE NO: 108 [SEQ ID NO: 108].
  • the analogues were administered at doses of 5, 800, 5 and 100 nmoles/kg respectively, by intraperitoneal injection to groups of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 18 to 21.
  • the analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
  • PEPTIDE NO: 142 [SEQ ID NO: 142]; PEPTIDE NO: 22 [SEQ ID NO:22]; PEPTIDE NO: 153 [SEQ ID NO: 153]; and PEPTIDE NO: 199 [SEQ ID NO: 199].
  • the analogues were administered at a dose of 3 nmoles/kg, 200 nmoles/kg (PEPTIDE NO: 153 [SEQ ID NO: 153]), and 500 nmoles/kg (PEPTIDE NO: 199 [SEQ ID NO: 199]) by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 22 to 25.
  • the analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control.
  • the food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
  • PEPTIDE NO: 210 [SEQ ID NO:210]
  • PEPTIDE NO: 211 [SEQ ID NO:211]
  • PEPTIDE NO: 213 [SEQ ID NO:213]
  • PEPTIDE NO: 214 [SEQ ID NO:214].
  • the analogues were administered at a dose of 20, 200, 400 and 400 nmoles/kg respectively by intraperitoneal injection to groups of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 48 hours is shown in comparison to saline in Figures 26 to 29.
  • the analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control.
  • the food intake suppression continues for the whole 48 hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 24 hours. It is also lower than in the control group treated with native oxyntomodulin.
  • PEPTIDE NO: 201 [SEQ ID NO:201]; and PEPTIDE NO: 202 [SEQ ID NO:202].
  • the analogues were administered at a dose of 5 nmoles/kg by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 48 hours is shown in comparison to saline in Figures 30 and 31.
  • the analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 48 hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 24 hours. It is also lower than in the control group treated with native oxyntomodulin.
  • PEPTIDE NO: 203 The feeding effect of the following analogue of oxyntomodulin was investigated: PEPTIDE NO: 203 [SEQ ID NO:203].
  • the analogue was administered at a dose of 100 nmoles/kg by subcutaneous injection to a group of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 32.
  • the analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
  • PEPTIDE NO: 204 [SEQ ID NO:204]
  • PEPTIDE NO: 205 SEQ ID NO:205
  • the analogues were administered at a dose of 5 nmoles/kg by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 32 hours is shown in comparison to saline in Figures 33 and 34.
  • the analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control.
  • the food intake suppression continues for the whole 32 hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 8 hours. It is also lower than in the control group treated with native oxyntomodulin.
  • PEPTIDE NO: 206 [SEQ ID NO:206]; PEPTIDE NO: 207 [SEQ ID NO:207]and PEPTIDE NO: 209 [SEQ ID NO:209].
  • the analogues were administered at a dose of 80 nmoles/kg by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 48 hours is shown in comparison to saline in Figures 35 to 37. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control.
  • the food intake suppression continues for the whole 48 hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 24 hours. It is also lower than in the control group treated with native oxyntomodulin.
  • Example 16 The feeding effect of the following analogue of oxyntomodulin was investigated: PEPTIDE NO: 215 [SEQ ID NO:215].
  • the analogue was administered at a dose of 5 nmoles/kg by subcutaneous injection to a group of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 38.
  • the analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
  • Example 17 The feeding effect of the following analogue of oxyntomodulin was investigated: PEPTIDE NO: 216 [SEQ ID NO:216].
  • the analogue was administered at a dose of 10 nmoles/kg by subcutaneous injection to a group of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 39.
  • the analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
  • PEPTIDE NO: 355 [SEQ ID NO:355].
  • the analogue was administered at a dose of 5 nmoles/kg by subcutaneous injection to a group of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 4 hours is shown in comparison to saline in Figure 40.
  • the analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 4 hour period; that is to say that the food intake over the 4 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
  • PEPTIDE NO: 130 [SEQ ID NO: 130].
  • the analogue was administered at a dose of 20 nmoles/kg by subcutaneous injection to a group of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 41.
  • the analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin. It will be appreciated that throughout the above examples, compounds of the invention are capable of inhibiting food intake at doses markedly lower than that of the native peptide used in the comparator experiments.

Abstract

The invention provides a peptide comprising the amino acid sequence given below, together with use of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity. Xaa1 Xaa2 Xaa3 Gly4 Thr5 Phe6 Thr7 Ser8 Asp9 Tyr1O Ser1 1 Lys12 Tyr13 Leu14 Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Trp25 Leu26 Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 Lys33 Asn34 Asn35 Ue36 Ala37; wherein: Xaa1 is His1 or D-His1, Xaa2 is Ser2 or Ala2, Xaa3 is Gln3 or Asp3; Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is: G1u15 Glu16 G1u17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Glu16 Glu17 Leul18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Glu16 Glu17 Leul18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24, Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Glu16 Glu17 Ilel18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24, Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Gln16 G1u17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ue23 Gln24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24, or Asp15 Ser16 Arg17 Arg18 Ala19 Gln20 Asp21 Phe22 Val23 Gln24; Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is: Met27 Asn28 Thr29 Lys30 Arg31 Asn32, Lys27 Asn28 Ala29 Gly30 Pro31 Ser32, or Lys27 Asn28 Gly29 Gly30 Pro31 Ser32 or a peptide as set out above in which residue Asn34 is replaced with Asp34; or a peptide as set out above in which Xaa3 is Glu3; with the proviso that if Xaal5 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is Asp15 Ser16 Arg17 Arg18 Ala19 Gln20 Asp21 Phe22 Val23 Gln24, - - then Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is not Met27 Asn28 Thr29 Lys30 Arg31 Asn32.

Description

NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR
1. FIELD OF THE INVENTION
This application relates to the use of agents to control appetite, feeding, food intake, energy expenditure and calorie intake, treat excess weight, obesity and to prevent and treat the comorbidities of obesity.
2. BACKGROUND OF THE INVENTION
According to the World Health Organisation (WHO), obesity represents a global epidemic in which more than one billion adults are overweight, of which at least 300 million are clinically obese. Furthermore, WHO estimate that 250,000 deaths per year in Europe, and more than 2.5 million deaths worldwide are weight related (World Health Organisation, Global Strategy on Diet, Physical Activity and Health, 2004).
The cause of obesity is complex and multi-factorial. Increasing evidence suggests that obesity is not a simple problem of self-control but is a complex disorder involving appetite regulation and energy metabolism. In addition, obesity is associated with a variety of conditions associated with increased morbidity and mortality in a population. Although the etiology of obesity is not definitively established, genetic, metabolic, biochemical, cultural and psychosocial factors are believed to contribute. In general, obesity has been described as a condition in which excess body fat puts an individual at a health risk.
There is strong evidence that obesity is associated with increased morbidity and mortality. Disease risk, such as cardiovascular disease risk and type 2 diabetes disease risk, increases independently with increased body mass index (BMI). Indeed, this risk has been quantified as a five percent increase in the risk of cardiac disease for females, and a seven percent increase in the risk of cardiac disease for males, for each point of a BMI greater than 24.9 (see Kenchaiah et al., N. Engl. J. Med. 347:305, 2002; Massie, N. Engl. J. Med. 347:358, 2002). In addition, there is substantial evidence that weight loss in obese or overweight persons reduces important disease risk factors. A weight loss of 10% of the initial body weight in both overweight and obese adults has been associated with a decrease in risk factors such as hypertension, hyperlipidemia, and hyperglycemia. Although diet and exercise provide a simple process to decrease weight gain and promote weight loss, overweight and obese individuals often cannot sufficiently control these factors to lose weight effectively. Pharmacotherapy is available; several weight loss drugs have been approved by the US Food and Drug Administration that can be used as part of a comprehensive weight loss program. However, many of these drugs have serious adverse side effects. An example of a widely used appetite suppressant is sibutramine (reviewed by McNeely, W et al., Drugs, 1998, 56(6), 1093-1124). Sibutramine's primary and secondary metabolites are pharmacologically active and they are thought to induce enhancement of satiety and thermogenesis by inhibiting serotonin and noradrenaline reuptake. When less invasive methods have failed, and the patient is at high risk for obesity related morbidity or mortality, weight loss surgery is an option in carefully selected patients with clinically severe obesity. However, these treatments are high-risk, and suitable for use in only a limited number of patients (Wolfe and Morton, JAMA, 2005, 294,1960-1963). It is not only obese subjects who wish to lose weight. People with weight within the recommended range, for example, in the upper part of the recommended range, may wish to reduce their weight, to bring it closer to the ideal weight.
Oxyntomodulin (hereafter oxm) is a 37 amino acid peptide member of the glucagon superfamily (Sherwood et al, Endocrine Reviews, 2000, 21(6): 619-670) comprising the entire 29 amino acid sequence of glucagon, with an eight amino acid carboxy terminal extension, resulting from the tissue-specific processing of the pre-pro-glucagon precursor in the brain and gut (Hoist, Ann Rev Physiol, 1997, 59:257-271). Administration of oxm to rats via intracerebro ventricular injection and injection into the paraventricular and arcuate nuclei of the hypothalamus inhibits refeeding after a fast (Dakin et al, Endocrinology, 2001, 142:4244- 4250; Dakin et al, Endocrinology, 2004, 145:2687-2695). Chronic central administration resulted in reduced weight gain consistent with a reduction in food intake (Dakin et al, Am J Physiol Endocrinol Metab, 2002, 283:E1173-E1177). Twice daily peripheral injections also resulted in reduced body weight gain and adiposity (Dakin et al, Endocrinology, 2004, 145:2687-2695).
WO 03/022304 discloses the use of oxm in its native form and analogues thereof as a medicament for use in control of appetite, feeding, food intake, energy expenditure and calorie intake, particularly in the field of obesity. Studies in humans have shown that intravenously infused oxm is an effective appetite suppressant (Cohen et al, J. Clin. Endocrinol Metab, 2003, 88(10): 4696-4701). In a study of the effects of oxm on weight loss in humans it was found that subcutaneous injections of 1.8 mg (approximately 400 nmol) of oxm to human volunteers three times daily (30 mins before meals) for 28 days resulted in a significant reduction of body weight (Wynne et al, Diabetes, 2005, 54: 2390-2395).
Peptides are widely used in medical practice, although when native peptides or analogues thereof are used in therapy it is generally found that they have a high clearance rate and/or are sensitive to degradation. In particular, a high clearance or rapid degradation of a therapeutic agent is inconvenient in cases where it is desired to maintain a high blood level over a prolonged period of time since repeat administrations will then be necessary, decreasing patient compliance and increasing the cost of the therapy.
A need remains for agents that can be used to effect weight loss in overweight and obese subjects, and/or to treat patients with other conditions involving excess weight, for example diabetes and eating disorders. There is especially a need for agents structurally similar to oxm that show greater potency and/or a protracted or more therapeutically useful profile of action and/or a lower clearance rate than native oxm.
3. SUMMARY OF THE INVENTION
Compounds of the invention are novel peptide analogues of oxm (hereafter "oxm analogues") in which one or more amino acids or parts of the oxm sequence have been replaced by one or more particular substituent amino acids or sequences. Accordingly, the invention provides a peptide comprising the amino acid sequence:
Xaal Xaa2 Xaa3 Gly4 Thr5 Phe6 Thr7 Ser8 Asp9 TyrlO Serl 1 Lysl2 Tyrl3 Leul4 Xaal5 Xaalό Xaal7 Xaal8 Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Trp25 Leu26 Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 Lys33 Asn34 Asn35 Ile36 Ala37; wherein:
Xaal is Hisl or D-Hisl, Xaa2 is Ser2 or Ala2, Xaa3 is Gln3 or Asp3; Xaal5 Xaalό Xaal7 Xaalδ Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
Glul5 Glulό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glulό Glul7 Leulδ Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glulό Glul7 Leulδ Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glulό Glul7 Leul δ Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glulό Glul7 Ilel δ Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, GIu 15 Glulό GIu 17 Ilelδ VaI 19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul 5 Glnl 6 Glul 7 Leul 8 VaI 19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glnlό Glul7 Leulδ Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnlβ Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul 5 Glnl 6 Glul 7 Ilel8 VaI 19 Lys20 Tyr21 Phe22 Ile23 Gln24, or Asp 15 Serl 6 Argl 7 Argl 8 Alal 9 Gln20 Asp21 Phe22 Val23 Gln24;
Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
Met27 Asn28 Thr29 Lys30 Arg31 Asn32, Lys27 Asn28 Ala29 Gly30 Pro31 Ser32, or Lys27 Asn28 Gly29 Gly30 Pro31 Ser32 or a peptide as set out above in which residue Asn34 is replaced with Asp34; or a peptide as set out above in which Xaa3 is Glu3; with the proviso that if
Xaal5 Xaalό Xaal7 Xaal8 Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is
Aspl5 Serl 6 Argl 7 Argl 8 Alal 9 Gln20 Asp21 Phe22 Val23 Gln24, then Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is not Met27 Asn28 Thr29 Lys30 Arg31 Asn32
(SEQ ID NO: 356).
In one embodiment, the invention provides a peptide comprising the amino acid sequence:
Xaal Xaa2 Xaa3 Gly4 Thr5 Phe6 Thr7 Ser8 Asp9 TyrlO Serl 1 Lysl2 Tyrl3 Leul4 Xaa 15 Xaa 16 Xaa 17 Xaa 18 Xaa 19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Tφ25 Leu26 Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 Lys33 Asn34 Asn35 Ile36 Ala37; wherein:
Xaal is Hisl or D-Hisl, Xaa2 is Ser2 or Ala2, Xaa3 is Gln3 or Asp3; Xaal5 Xaalό Xaal7 Xaal8 Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
Glul5 Glulό Glul7 Leul 8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glulό Glul7 Leul 8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glulό Glul7 Leul 8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glulό Glul7 Leul 8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glulό Glul7 Ilel 8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glulό Glul7 Ilel 8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul 5 Glulό GIu 17 He 18 VaI 19 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnlό Glul7 Leulδ Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glnlδ Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glnlό Glul7 Leulδ Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glul5 Glnlβ Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glnlδ Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glnlβ Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, or Aspl5 Serlό Argl7 Arglδ Alal9 Gln20 Asp21 Phe22 Val23 Gln24;
Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
Met27 Asn28 Thr29 Lys30 Arg31 Asn32, Lys27 Asn28 Ala29 Gly30 Pro31 Ser32, or Lys27 Asn28 Gly29 Gly30 Pro31 Ser32 with the proviso that if
Xaal5 Xaalό Xaal7 Xaalδ Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is Aspl5 Serlό Argl7 Argl8 Alal9 Gln20 Asp21 Phe22 Val23 Gln24, then Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is not Met27 Asn28 Thr29 Lys30 Arg31 Asn32.
The peptides of the invention are potent and long-lasting appetite suppressants.
4. BRIEF DESCRIPTION OF THE FIGURES
Figure 1 discloses 355 specific peptide sequences falling within the scope of the invention. Figures 2 to 41 show the results of Examples 1 to 19. Figure 2 relates to Example 1.
Figure 3 relates to Example 2.
Figure 4 relates to Example 3 (PEPTIDE NO: 94).
Figure 5 relates to Example 3 (PEPTIDE NO: 82). Figure 6 relates to Example 3 (PEPTIDE NO: 58).
Figure 7 relates to Example 3 (PEPTIDE NO: 52).
Figure 8 relates to Example 4 (PEPTIDE NO: 164).
Figure 9 relates to Example 4 (PEPTIDE NO: 167).
Figure 10 relates to Example 5 (PEPTIDE NO: 100). Figure 1 1 relates to Example 5 (PEPTIDE NO: 148). Figure 12 relates to Example 6 (PEPTIDE NO: 60). Figure 13 relates to Example 6 (PEPTIDE NO: 178).
Figure 14 relates to Example 7 (PEPTIDE NO: 155). Figure 15 relates to Example 8 (PEPTIDE NO: 142).
Figure 16 relates to Example 8 (PEPTIDE NO: 172).
Figure 17 relates to Example 8 (PEPTIDE NO: 184).
Figure 18 relates to Example 9 (PEPTIDE NO: 4).
Figure 19 relates to Example 9 (PEPTIDE NO: 108). Figure 20 relates to Example 9 (PEPTIDE NO: 195).
Figure 21 relates to Example 9 (PEPTIDE NO: 136).
Figure 22 relates to Example 10 (PEPTIDE NO: 142).
Figure 23 relates to Example 10 (PEPTIDE NO: 22).
Figure 24 relates to Example 10 (PEPTIDE NO: 153). Figure 25 relates to Example 10 (PEPTIDE NO: 199).
Figure 26 relates to Example 11 (PEPTIDE NO: 210).
Figure 27 relates to Example 11 (PEPTIDE NO: 211).
Figure 28 relates to Example 11 (PEPTIDE NO: 213).
Figure 29 relates to Example 11 (PEPTIDE NO: 214). Figure 30 relates to Example 12 (PEPTIDE NO: 201).
Figure 31 relates to Example 12 (PEPTIDE NO: 202).
Figure 32 relates to Example 13 (PEPTIDE NO: 203).
Figure 33 relates to Example 14 (PEPTIDE NO: 204).
Figure 34 relates to Example 14 (PEPTIDE NO: 205). Figure 35 relates to Example 15 (PEPTIDE NO: 206).
Figure 36 relates to Example 15 (PEPTIDE NO: 207).
Figure 37 relates to Example 15 (PEPTIDE NO: 209).
Figure 38 relates to Example 16 (PEPTIDE NO: 215).
Figure 39 relates to Example 17 (PEPTIDE NO: 216). Figure 40 relates to Example 18 (PEPTIDE NO: 355). Figure 41 relates to Example 19 (PEPTIDE NO: 130).
5. DEFINITIONS In order to facilitate review of the various embodiments of this disclosure, the following explanations of specific terms are provided:
Animal: Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds. The term mammal includes both human and non-human mammals. Similarly, the term "subject" includes both human and non-human subjects, including veterinary subjects.
Appetite: A natural desire, or longing for food. In one embodiment, appetite is measured by a survey to assess the desire for food. Increased appetite generally leads to increased feeding behavior.
Appetite Suppressants: Compounds that decrease the desire for food. Commercially available appetite suppressants include, but are not limited to, amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine fenfluramine, dexfenfluramine, sibutramine, rimonabant and fluoxetine.
Body Mass Index (BMI): A mathematical formula for measuring body mass, also sometimes called Quetelet's Index. BMI is calculated by dividing weight (in kg) by height2 (in meters2). The recommended classifications for BMI in humans, adopted by the Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults, and endorsed by leading organizations of health professionals, are as follows: Underweight <18.5 kg/m2; Normal weight 18.5-24.9 kg/m2; Overweight 25-29.9 kg/m2; Obesity (Class 1) 30-34.9 kg/m2; Obesity (Class 2) 35-39.9 kg/m2; Extreme obesity (Class 3) >40 kg/m2 (Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults, The North American Association for the Study of Obesity (NAASO) and the
National Heart, Lung, and Blood Institute (NHLBI) 2000). In one embodiment, a BMI of greater than 25 kg/m2 can be used to identify a subject in need of a treatment for excess weight or obesity. Ideal body weight will vary among species and individuals based on height, body build, bone structure, and sex.
Conservative substitutions: The replacement of an amino acid residue by another similar residue in a polypeptide. Typical but not limiting conservative substitutions are the replacements, for one another, among the aliphatic amino acids Ala, VaI, Leu and He; interchange of Ser and Thr containing hydroxy residues, interchange of the acidic residues Asp and GIu, interchange between the amide-containing residues Asn and GIn, interchange of the basic residues Lys and Arg, interchange of the aromatic residues Phe and Tyr, and interchange of the small-sized amino acids Ala, Ser, Thr, Met and GIy. Additional conservative substitutions include the replacement of an amino acid by another of similar spatial or steric configuration, for example the interchange of Asn for Asp, or GIn for GIu.
Table 1 : Non-limiting examples of conservative amino acid substitutions
Original Residue Conservative Substitutions
Ala GIy, VaI, Leu, He, Ser, Thr, Met
Arg Lys
Asn Asp, GIn, His Asp GIu, Asn
Cys Ser
GIn Asn, His, Lys, GIu
GIu Asp, GIn
GIy Ala, Ser, Thr, Met His Asn, GIn
He Ala, Leu, VaI, Met
Leu Ala, He, VaI, Met,
Lys Arg
Met Leu, He, Ala, Ser, Thr, GIy Phe Leu, Tyr, Trp
Ser Thr, Cys, Ala, Met, GIy
Thr Ser, Ala, Ser, Met, GIy
Trp Tyr, Phe
Tyr Trp; Phe VaI Ala, He, Leu
Non-conservative substitutions: The replacement, in a polypeptide, of an amino acid residue by another residue which is not biologically similar. For example, the replacement of an amino acid residue with another residue that has a substantially different charge, a substantially different hydrophobicity or a substantially different spatial or steric configuration.
The phrase "alternative amino acid" encompasses alternative amino acids that are the result of both conservative and non-conservative substitutions. In addition to the twenty commonly occurring amino acids that are typically found in naturally occurring polypeptides, rare amino acids, for example, canavanine, ornithine and 5-hydroxytryptophane, and artificial amino acids, that is to say amino acids not normally found in vivo, for example t-butylglycine, may be used as "alternative amino acids" in accordance with the invention. Any chiral form of an amino acid may be used.
Diabetes: A failure of cells to transport endogenous glucose across their membranes either because of an endogenous deficiency of insulin and/or a defect in insulin sensitivity. Diabetes is a chronic syndrome of impaired carbohydrate, protein, and fat metabolism owing to insufficient secretion of insulin or to target tissue insulin resistance. It occurs in two major forms: insulin-dependent diabetes mellitus (IDDM, type I) and non-insulin dependent diabetes mellitus (NIDDM, type II) which differ in etiology, pathology, genetics, age of onset, and treatment.
The two major forms of diabetes are both characterised by an inability to deliver insulin in an amount and with the precise timing that is needed for control of glucose homeostasis. Diabetes type I, or insulin dependent diabetes mellitus (DDDM) is caused by the destruction of pancreatic β cells, which results in insufficient levels of endogenous insulin. Diabetes type II, or non-insulin dependent diabetes, results from a defect in both the body's sensitivity to insulin, and a relative deficiency in insulin production.
Food intake: The amount of food consumed by an individual subject. Food intake can be measured by volume or by weight. For example, food intake may be the total amount of food consumed by an individual subject. Or, food intake may be the amount of proteins, fat, carbohydrates, cholesterol, vitamins, minerals, or any other food component, of the individual subject. "Protein intake" refers to the amount of protein consumed by an individual. Similarly, "fat intake," "carbohydrate intake," "cholesterol intake," "vitamin intake," and "mineral intake" refer to the amount of fat, carbohydrates, cholesterol, vitamins, or minerals consumed by an individual subject respectively.
Normal Daily Diet: The average food intake for an individual of a given species. A normal daily diet can be expressed in terms of caloric intake, protein intake, carbohydrate intake, and/or fat intake. A normal daily diet in humans generally comprises the following: about
2,000, about 2,400, or about 2,800 to significantly more calories. In addition, a normal daily diet in humans generally includes about 12 g to about 45 g of protein, about 120 g to about 61O g of carbohydrate, and about 11 g to about 90 g of fat. A low calorie diet would be no more than about 85%, and preferably no more than about 70%, of the normal caloric intake of a human individual. In animals, the caloric and nutrient requirements vary depending on the species and size of the animal. For example, in cats, the total caloric intake per pound, as well as the percent distribution of protein, carbohydrate and fat varies with the age of the cat and the reproductive state. A general guideline for cats, however, is 40 cal/lb/day (18.2 cal/kg/day). About 30% to about 40% should be protein, about 7% to about 10% should be from carbohydrate, and about 50% to about 62.5% should be derived from fat intake. One of skill in the art can readily identify the normal daily diet of an individual of any species.
Obesity: A condition in which excess body fat may put a person at health risk (see Barlow and Dietz, Pediatrics 102:E29, 1998; National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Obes. Res. 6 (suppl. 2):51S-209S, 1998). Excess body fat is a result of an imbalance of energy intake and energy expenditure. For example, the Body Mass Index (BMI) may be used to assess obesity. In one commonly used convention, a BMI of 25.0 kg/m2 to 29.9 kg/m2 is overweight, while a BMI of 30 kg/m2 or greater is obese.
In another convention, waist circumference is used to assess obesity. Excess abdominal fat is an important, independent assessment of the risks associated with obesity or being overweight. Waist circumference measurement is particularly useful in patients who are categorised as normal or overweight. It is not usually necessary to measure waist circumference in individuals with BMIs > 35 kg/m2 since it adds little to the predictive power of the disease risk classification of BMI. Men who have waist circumferences greater than 40 inches (102 cm), and women who have waist circumferences greater than 35 inches (90 cm), are at higher risk of diabetes, dyslipidemia, hypertension, and cardiovascular disease because of excess abdominal fat. Individuals with waist circumferences greater than these values should be considered one risk category above that defined by their BMI.
Strong evidence shows that obesity affects both the morbidity and mortality of individuals. For example, an overweight or obese individual is at increased risk for heart disease, non- insulin dependent (type 2) diabetes, hypertension, stroke, cancer (e.g. endometrial, breast, prostate, and colon cancer), dyslipidemia, gall bladder disease, sleep apnea, reduced fertility, and osteoarthritis, amongst others (see Lyznicki et al., Am. Fam. Phys. 63:2185, 2001).
Overweight: An individual who weighs more than their ideal body weight. An overweight individual can be obese, but is not necessarily obese. For example, an overweight individual is any individual who desires to decrease their weight. In one convention, an overweight individual is an individual with a BMI of 25.0 kg/m2 to 29.9 kg/m2. Pegylation: the process of reacting a poly(alkylene glycol), preferably an activated poly(alkylene glycol) to form a covalent bond. A facilitator may be used, for example an amino acid, e.g. lysine. Although "pegylation" is often carried out using poly(ethylene glycol) or derivatives thereof, such as methoxy poly(ethylene glycol), the term is not limited herein to the use of methoxy poly(ethylene glycol) but also includes the use of any other useful poly(alkylene glycol), for example poly(propylene glycol). Pegylated shall be defined accordingly.
Peripheral Administration: Administration outside of the central nervous system. Peripheral administration does not include direct administration to the brain. Peripheral administration includes, but is not limited to intravascular, intramuscular, subcutaneous, inhalation, oral, rectal, transdermal, buccal, sub-lingual or intra-nasal administration
Polypeptide: A polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L- optical isomer or the D-optical isomer can be used, the L-isomers being preferred. Throughout this specification, an alpha-amino acid will be assumed to be the L-isomer if it not explicitly stated to be the D-isomer. The terms "polypeptide" or "protein" as used herein encompass any amino acid sequence and include modified sequences such as glycoproteins. The term "polypeptide" covers naturally occurring proteins, as well as those which are recombinantly or synthetically produced. The term "polypeptide fragment" refers to a portion of a polypeptide, for example such a fragment which exhibits at least one useful sequence in binding a receptor. The term "functional fragments of a polypeptide" refers to all fragments of a polypeptide that retain an activity of the polypeptide. Biologically functional peptides can also include fusion proteins, in which the peptide of interest is fused to another peptide(s).
Therapeutically effective amount: A dose sufficient to prevent advancement, or to cause regression of a disorder, or which is capable of relieving a sign or symptom of a disorder, or which is capable of achieving a desired result. In several embodiments, a therapeutically effective amount of a compound of the invention is an amount sufficient to inhibit or halt weight gain, or an amount sufficient to decrease appetite, or an amount sufficient to reduce caloric intake or food intake or increase energy expenditure, or an amount sufficient to reduce weight, or to reduce the risk of mortality or morbidity from conditions associated with the disorder.
6. DETAILED DESCRIPTION The inventors have found that, surprisingly, oxm analogues of the invention are effective appetite suppressants and/or have a more sustained effect than native oxm on food intake, and/or have a more potent effect than native oxm on food intake.
The human oxm sequence (which is the same as the rat and hamster) is as follows:
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn lie Ala (SEQ ID NO: 357)
The peptides of the invention also have a longer half-life or clearance time or improved resistance to degradation as compared with oxm. Increased duration of appetite suppression can be particularly important to avoid the effect known as "escape". A short duration appetite suppressant may reduce appetite for the time covered by one meal and, in that meal, the subject typically eats less food. If, however, the appetite suppressant has a short half-life or rapid clearance time or is then metabolized or otherwise removed from the circulation of the subject, then by the time of the next mealtime, the subject can regain its "normal" appetite. In view of the subject having eaten a small meal at the previous mealtime, the subject may in fact have an increased appetite by the time of the subsequent meal. If the subject satisfies that appetite, it is possible for the food intake over the two meals, in total, to be no lower than the food intake would have been without the appetite suppressant. That is to say that the subject may have "escaped" from the effects of the appetite suppressant. "Escape" can be reduced by using additional doses of appetite suppressant, or by using an appetite suppressant with a longer duration of action. If the subject has a reduced appetite for longer, then the degree to which it can make up the missed food from one meal in the next meal is reduced as there is a practical limit to the total capacity for food in a particular meal. Repeated or continuous administration of a compound over a period of time, for example over a period of days or weeks, will lead to extended appetite suppression and reduced potential for escape from the effects of the appetite suppression.
The improved activity and/or duration of action of the oxm analogues as compared with oxm offers various advantages. For example, effective suppression of appetite at lower dosages will be permitted (with the lower dosage and/or lower peak levels, offering the prospect of reduced side effects (including nausea) and reduction in the cost of treatment), or usage at relatively high dosages will be better tolerated by the patient enabling quicker and/or greater weight loss. Certain of the compounds of the invention used in the Examples herein exhibit a pattern of appetite suppression indicative of a 'flatter blood curve', that is to say they have improved pharmacokinetids, by virture of displaying either or both of (i) a more gradual onset of the appetite suppressant activity than oxm and thereby potentially avoid an initial sharp peak (which may be associated with nausea); and (ii) a potentially longer duration of action.
Further advantages of many compounds of the invention include that the compounds have improved storage characteristics and are amenable to large scale synthesis, for example some compounds of the invention do not contain sequence motifs associated with the formation of aspartimide species, and/or are less prone to reduced stability.
In one embodiment, the invention provides a peptide wherein
Xaal5 Xaal6 Xaal7 Xaalδ Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
Glul5 Glulό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glulό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glulό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24,
Glul5 Glulό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, or Glul 5 Glnl 6 Glul 7 Ilel 8 VaI 19 Lys20 Tyr21 Phe22 Ile23 Gln24. (SEQ ID NO: 359).
In particular embodiments, a peptide of the invention is one wherein
Xaal5 Xaalό Xaal7 Xaalδ Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is: Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glulό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, or Glul5 Glulό Glul7 Leul 8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24.
In a further embodiment, a peptide of the invention is one wherein Xaal5 Xaalό Xaal7 Xaal8 Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
Aspl5 Serlό Argl7 Argl δ Alal9 Gln20 Asp21 Phe22 Val23 Gln24.
In a further embodiment, a peptide of the invention comprises Xaal Xaa2 Xaa3 selected from the group consisting of:
Hisl Ser2 Gln3, D-His 1 Ser2 Gln3, D-His 1 Ala2 Gln3, and D-His 1 Ala2 Asp3. (SEQ ID NO: 360).
In a further embodiment, a peptide of the invention is one wherein
Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is: Lys27 Asn28 Ala29 Gly30 Pro31 Ser32,
Lys27 Asn28 Gly29 Gly30 Pro31 Ser32, or Met27 Asn28 Thr29 Lys30 Arg31 Asn32.
In a further embodiment, a peptide of the invention is one wherein
Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
Lys27 Asn28 Ala29 Gly30 Pro31 Ser32, or Lys27 Asn28 Gly29 Gly30 Pro31 Ser32
(SEQ ID NO: 361).
In one embodiment, a peptide of the invention is one wherein Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
Lys27 Asn28 Ala29 Gly30 Pro31 Ser32.
In particular, the peptide of the invention may have an amino acid sequence selected from the group comprising:
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 1)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 2) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys
Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 3)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 4)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 5)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 6) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO:
7) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys
Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 8)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe lie GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ E)
NO: 9)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 10)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO:
H)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Ue GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ H) NO: 12) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys
Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 13)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 14)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 15)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ HD NO: 16)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ K) NO: 17) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys
Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 18)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO:
19)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 20) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu lie VaI Lys Tyr Phe He GIu Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 21)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 22) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys
Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO:
23)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID
NO: 24)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 25)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 26)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 27) HisSer GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys
Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 28)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ HD
NO: 29)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 30)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ YD NO: 31)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 32) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys
Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ H) NO: 33) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 34) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys
Tyr Phe lie GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 35)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID
NO: 36)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 37)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ H) NO: 38)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 39) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys
Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 40)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 41)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 42)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ H) NO: 43)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ JD NO: 44) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys
Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 45)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO:
46)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ JD NO: 47) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ HD NO: 48)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 49) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ TD NO: 50)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 51)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ H) NO: 52)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 53)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 54) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 55)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 56)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 57)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 58)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 59) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 60) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 61) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe Leu GIu Tip Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 62)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 63)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 64)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 65)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 66) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 67)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 68)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 69)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 70)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 71) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIn Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 72)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 73)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 74) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 75)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 76) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 77)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 78)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ TD NO: 79)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 80)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 81) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 82)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 83)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 84)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 85)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 86) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 87) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu lie VaI Lys Tyr Phe Leu GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 88) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu lie VaI
Lys Tyr Phe Leu GIn Tip Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 89)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu lie VaI Lys Tyr Phe Leu GIn Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 90)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 91)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 92)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ JD NO: 93) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 94)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ JD
NO: 95)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 96)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 97)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 98) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 99)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 100)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 101) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 102)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 103) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 104)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 105)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 106)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 107)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 108) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 109)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 1 10)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 1 1 1)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 1 12)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 113) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 114) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 115) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 116)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 117)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 118)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 119)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Ue GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 120) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 121)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 122)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 123)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 124)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 125) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 126)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 127)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 128) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn lie Ala (SEQ ID NO: 129)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 130) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe lie GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 131)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 132)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 133)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 134)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 135) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 136)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 137)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 138)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 139)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 140) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 141) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 142) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 143)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 144)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ H) NO: 145)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Tip Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 146)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ K) NO: 147) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 148)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn Ue Ala (SEQ
H) NO: 149)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 150)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 151)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 152) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 153)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 154)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 155) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe lie GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 156)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 157) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 158)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu lie VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 159)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 160)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 161)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 162) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 163)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 164)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 165)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 166)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 167) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 168) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 169) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 170)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 171)
D.His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 172)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 173)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 174) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 175)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 176)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 177)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 178)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 179) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 180)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 181)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 182) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn Ue Ala (SEQ ID NO: 183)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 184) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 185)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 186)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 187)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 188)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 189) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 190)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 191)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 192) ple, the peptide of the invention may have the amino acid sequence
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 193)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 194)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 195) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Tip Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 196) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala
GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 197)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 198)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 199)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 200)
Optionally, the peptide of the invention has an extension moiety -A-B-C at the C-terminus. Accordingly, the peptide of the invention may have an additional extension moiety of sequence -A-B-C, wherein:
A is absent or 1, 2, 3 or 4 Ala residues or 1, 2, 3 or 4 GIu residues B is absent or 1 , 2, 3 or 4 Ala residues or 1 , 2, 3 or 4 GIu residues provided that A and B do not both comprise Ala residues, and that A and B do not both comprise GIu residues; and
C is Lys, or Lys with an acid selected from capric acid, lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid, attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
In one embodiment, groups A or B or both A and B are absent. In an embodiment when A and B are both present, A is GIu and B is Ala. For example, in one embodiment A is one GIu residue, and B is one Ala residue.
In one embodiment, C is a Lys residue without substitution.
In one embodiment, C is a Lys residue with a fatty acid attached via its -COOH group to the - NH2 group of the Lys side chain by means of a peptide bond. For example, the fatty acid may be selected from
- capric acid
- lauric acid
- myristic acid, - palmitic acid,
- stearic acid, and
- arachidic acid, (icosanoic acid)
In further emobodiments, the C-terminal extension moiety -A-B-C is: Lys38,
Lys38-caproyl
Lys38-lauroyl,
Lys38-myristoyl, Lys38-palmitoyl,
Lys38-stearoyl,
Lys38 -arachidoyl ,
Glu38 Ala39 Lys40,
Glu38 Ala39 Lys40-caproyl, Glu38 Ala39 Lys40-lauroyl,
Glu38 Ala39 Lys40-myristoyl,
Glu38 Ala39 Lys40-palmitoyl,
Glu38 Ala39 Lys40-stearoyl, or Glu38 Ala39 Lys40-arachidoyl.
The arachidoyl group is also known as the icosanoyl group.
Exemplary compounds comprising the C-termainal extension moiety -A-B-C may be selected from the group comprising:
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 201) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu lie VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 202)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala Lys
(SEQ ID NO: 203)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 204)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 205)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-myristoyl (SEQ ID NO: 206) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-palmitoyl (SEQ ID NO: 207)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala
Lys-stearoyl (SEQ ID NO: 208) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-arachidoyl (SEQ ID NO: 209) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys (SEQ HD NO: 210)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala
Lys-myristoyl (SEQ ID NO: 211)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-myristoyl (SEQ ID NO : 212)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-palmitoyl (SEQ ID NO: 213)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-arachidoyl (SEQ ID NO: 214)
As mentioned above, the native human oxm sequence (which is the same as the rat and hamster) is as follows:
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn He Ala (SEQ ID NO: 357)
The native bovine oxm sequence (which is the same as the porcine) is as follows:
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 358)
That is to say that it is the same as the human sequence except that Arg33 in the human peptide is replaced by Lys33 in the bovine peptide. The present invention provides analogues of oxyntomodulin as set out above. The invention further provides peptides that are analogues in which the Lys33 residue of the peptide recited above is replaced with Arg33.
In an embodiment, the invention provides a peptide of the invention in which residue Asn34 is replaced with Asp34. Certain peptides with Asn34 replaced by Asp34 are shown as PEPTIDES No 215 to 292 in Figure 1. In a further embodiment, the invention provides a peptide in which residue Gln3 or Asp3 is replaced with Glu3. Certain peptides with Glu3 are shown as PEPTIDES No 293 to 355 in Figure 1.
The invention further comprises embodiments incorporating the sequences disclosed in the attached examples and/or figures.
Derivatives
A compound of the invention may comprise a structure set forth above, modified by well known processes including amidation, glycosylation, carbamylation, alkylation, acylation, for example acetylation, sulfation, phosphorylation, cyclization, lipidization, protein (for example albumin) conjugation and pegylation. Analogues of the invention may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.
A compound of the invention may be a fusion protein, whereby the analogue of oxyntomodulin is fused to another protein or polypeptide (the fusion partner) using recombinant methods known in the art. Alternatively, such a fusion protein may be synthetically synthesized by any known method. Such a fusion protein comprises the analogue of oxyntomodulin. Any suitable peptide or protein can be used as the fusion partner (e.g., serum albumin, carbonic anhydrase, glutathione-S-transferase, single chain antibodies, antibodies, antibody fragments or thioredoxin, etc.). For example, a compound of the invention could be fused to an immunoglobulin light chain variable domain that has binding specificity for serum albumin, as described in WO 05/118642. Preferred fusion partners will not have an adverse biological activity in vivo.
Such fusion proteins, including hybrid polypeptides, may be made by linking the carboxy- terminus of the fusion partner to the amino-terminus of the analogue of oxyntomodulin or vice versa, directly, or via a linker that preferably does not involve the loss of activity of components. Where present, the linker may be chemically stable, or labile, for example a cleavable linker may be used to link the analogue of oxyntomodulin to one or more fusion partners. A resulting cleavable fusion protein may be cleaved in vivo such that an active form of a compound of the invention is released. Examples of such cleavable linkers include, but are not limited to, the linkers D-D-D-D-Y, G-P-R, A-G-G and H-P-F-H-L, which can be cleaved by enterokinase, thrombin, ubiquitin cleaving enzyme and renin, respectively. See, e.g., U.S. Patent No. 6,410,707. Alternatively a compound of the invention may be a fusion protein, whereby the structure of the compound of the invention is attached to a fusion partner via disulphide bond(s) resulting in a covalent linkage between at least one Cys residue of the compound of the invention, and at least one Cys residue of the fusion partner.
When a protein is used as a fusion partner, it is preferably chosen so as not to exhibit undesirable antigenicity. Undesirable antigenicity may be avoided by chosing a protein which is allogenic to the animal to which the compound is to be administered.
A compound of the invention may be a physiologically functional derivative of a compound of the invention. The term "physiologically functional derivative" is used herein to denote a chemical derivative of a compound of the invention having the same physiological function as the corresponding unmodified compound of the invention. For example, a physiologically functional derivative may be convertible in the body to a compound of the invention. According to the present invention, examples of physiologically functional derivatives include esters, amides, and carbamates; preferably esters and amides.
Pharmaceutically acceptable esters and amides of the compounds of the invention may comprise a Ci.6 alkyl-, C5-10 aryl-, C5-I0 ar-Ci_6 alkyl-, or amino acid-ester or -amide attached at an appropriate site, for example at an acid group.
Acyl side chains may be advantageous, for example, by their lipophilic nature causing the moiety to bind with albumin, thus causing a greatly reduced rate of clearance from a subject and so increasing half life and duration of effect. Whilst the acyl side chains may be lower acyl, for example Cp C9 acyl, especially C\.b acyl, they are preferred to be C4-40, in particular C8-25 acyl, especially C]6 or Qg acyl. Palmitoyl is especially preferred as an acyl side chain as is lauroyl. Acyl side chains may be added at any position on the peptide back bone. An acyl substituent may be attached to an amino acid residue in such a way that a carboxyl group of the acyl substituent forms an amide bond with an amino group of the amino acid residue. Alternatively, an acyl substituent may be attached to an amino acid residue in such a way that an amino group of the acyl substituent forms an amide bond with a carboxyl group of the amino acid residue. In a further preferred embodiment, the present invention relates to an oxm derivative wherein an acyl substituent is attached to the parent peptide by means of a spacer. For example, the acyl substituent may be attached to the oxm moiety by means of a spacer in such a way that a carboxyl group of the spacer forms an amide bond with an amino group of the oxm moiety. It is especially preferred to add an acyl side chain (optionally via a spacer) at a position in the peptide back bone where a lysine residue is found. This is because lysine, having a four carbon atom side chain terminating at an epsilon-amino group, is particularly suitable for easily adding an acyl side chain. It may be necessary to introduce lysine residue into the sequence solely for the purpose of providing a convenient site at which to add an acyl side chain. Alternatively the acyl side chain may be added to the lysine residue in advance of the synthesis of the peptide, whereupon its incorporation at the relevant synthetic step will result directly in acylation. This methodology is advantageous if the peptide sequence contains more than one lysine residue as it avoids the necessity of using selective conditions that acylate only the particular lysine of interest. Preferably, the peptide derivatives have three, more preferably two, and most preferably one acyl side chain substituent. Examples of acyl (and other lipophilic substituents), approaches and specific synthetic methods of attaching such to peptides (with and without the use of spacers) are described in U.S. Patent No. 6,268,343; and U.S. Patent Number 6,458,924. Further examples of saturated fatty acids suitable for acyl derivatisation of compounds of the invention are butyric (butanoic acid): CH3(CH2)JCOOH; caproic (hexanoic acid):
CH3(CH2)4COOH; caprylic (octanoic acid): CH3(CH2)6COOH; capric (decanoic acid): CH3(CH2)8COOH; lauric (dodecanoic acid): CH3(CH2)i0COOH; myristic (tetradecanoic acid): CH3(CH2)i2COOH; palmitic (hexadecanoic acid): CH3(CH2)i4COOH; stearic (octadecanoic acid): CH3(CH2) ,6COOH; arachidic (eicosanoic acid): CH3(CH2)i8COOH; behenic (docosanoic acid): CH3(CH2)20COOH.
According to certain preferred embodiments, acyl side chains may be added at position 30 and/or position 33 and/or positions 38 to 46 of the peptide back bone.
Pharmaceutically acceptable amides and carbonates of the compounds of Formula (I) may comprise a Ci_6 alkyl-, C5-I0 aryl-, C5.10 ar-C|.6 alkyl-, or amino acid-ester or -amide, or - carbamate attached at an appropriate site, for example at an amino group.
Methods for lipidization of sulfhydryl-containing compounds with fatty acid derivatives are disclosed in U.S. Patent No. 5,936,092; U.S. Patent No. 6,093,692; and U.S. Patent No. 6,225,445. Fatty acid derivatives of a compound of the invention comprising a compound of the invention linked to fatty acid via a disulfide linkage may be used for delivery of a compound of the invention to neuronal cells and tissues. Lipidisation markedly increases the absorption of the compounds relative to the rate of absorption of the corresponding unlipidised compounds, as well as prolonging blood and tissue retention of the compounds. Moreover, the disulfide linkage in lipidised derivative is relatively labile in the cells and thus facilitates intracellular release of the molecule from the fatty acid moieties. Suitable lipid- containing moieties are hydrophobic substituents with 4 to 26 carbon atoms, preferably 5 to 19 carbon atoms. Suitable lipid groups include, but are not limited to, the following: palmitoyl (Ci5H3I,), oleoyl (C15H29), stearoyl (C17H35), cholate; and deoxycholate.
It will be appreciated by the skilled artisan that particular amino acid residues may be introduced to the oxm sequence in order to facilitate one or more of the modifications described herein.
Cyclization methods include cyclization through the formation of a disulfide bridge and head- to-tail cyclization using a cyclization resin. Cyclized peptides may have enhanced stability, including increased resistance to enzymatic degradation, as a result of their conformational constraints. Cyclization may in particular be expedient where the uncyclized peptide includes an N-terminal cysteine group. Suitable cyclized peptides include monomelic and dimeric head-to-tail cyclized structures. Cyclized peptides may include one or more additional residues, especially an additional cysteine incorporated for the purpose of formation of a disulfide bond or a side chain incorporated for the purpose of resin-based cyclization.
A compound of the invention may be pegylated. Pegylated compounds of the invention may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337). WO 2006/082517 and US 2006/171920, which are incorporated herein by reference, provide examples and associated methods of pegylating peptides and analogues and derivatives thereof.
Chemical moieties for derivitization of a compound of the invention may also be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. A polymer moiety for derivatisation of a compound of the invention may be of any molecular weight, and may be branched or unbranched. For ease in handling and manufacturing, the preferred molecular weight of a polyethylene glycol for derivatisation of a compound of the invention is from about 1 kDa to about 100 kDa, the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight. Polymers of other molecular weights may be used, depending on the desired therapeutic profile, for example the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog. For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.
Salts and solvates of compounds of the invention that are suitable for use in a medicament are those wherein a counterion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of the compounds of the invention and their pharmaceutically acceptable salts or solvates.
Suitable salts according to the invention include those formed with organic or inorganic acids or bases. Pharmaceutically acceptable acid addition salts include those formed with hydrochloric, hydrobromic, sulphuric, nitric, citric, tartaric, acetic, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, succinic, perchloric, fumaric, maleic, glycollic, lactic, salicylic, oxaloacetic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic, and isethionic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutical acceptable salts. Pharmaceutically acceptable salts with bases include ammonium salts, alkali metal salts, for example potassium and sodium salts, alkaline earth metal salts, for example calcium and magnesium salts, and salts with organic bases, for example dicyclohexylamine and N-methyl- D-glucomine.
Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. Such complexes are known as "solvates". For example, a complex with water is known as a "hydrate". The present invention provides solvates of compounds of the invention.
Peptides of the invention may be made by any suitable technique for making peptides, including but not limited to conventional methodology, for example, synthesis from individual amino acids, especially step-wise synthesis using an automatic peptide synthesizer; modification of native peptides; or recombinant manufacturing techniques.
Conditions The invention provides a pharmaceutical composition comprising a peptide according to the invention and one or more pharmaceutically acceptable carriers. The invention also provides a pharmaceutical composition for use in the control of appetite, feeding, food intake, energy expenditure and calorie intake, the composition comprising an effective amount of a compound according to the invention. More particularly, the invention provides a pharmaceutical composition for use in the treatment of obesity, for use in the treatment of eating disorders, or for use in the treatment of diabetes or a symptom of diabetes, or for use in the treatment or prevention of comorbidities associated with obesity or excess weight.
Moreover, the invention provides a method of reducing excess weight, for example cosmetic excess weight, comprising administering to a patient desiring to reduce weight an effective amount of a compound or a pharmaceutical composition according to the invention.
Furthermore, the invention provides a method of of treating or preventing obesity or diabetes or another co-morbitity of obesity in a subject in need thereof comprising administering to the subject an effective amount of a compound or a pharmaceutical composition according to the invention.
The invention also provides a method of reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject in need thereof comprising administering to the subject a peptide or a pharmaceutical composition according to the invention.
The invention also provides a method of causing weight loss or preventing weight gain for cosmetic purposes comprising administering to the subject a peptide or a pharmaceutical composition according to the invention.
The invention also provides a peptide of the invention for use as a medicament. It may for use as a medicament for the treatment of obesity or diabetes or of a co-morbidity of obesity. It may be for use as a medicament for reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject. The invention also provides use of a compound according to the invention in the manufacture of a medicament for use in the treatment of a condition selected from obesity, eating disorders, diabetes, heart disease, hypertension, lipid disease, and disorders of intestinal and gastric motor activity and other aspects of gut and intestinal function, for example, water absorption and fluid handling, or pancreatic function including the endocrine pancreas, or disorders of hepato-biliary function, or prevention of cancer. In particular, the invention provides the use of a peptide of the invention for the manufacture of a medicament for the treatment of obesity or diabetes or of a co-morbidity of obesity. Further, the invention provides use of a compound according to the invention in the manufacture of a medicament for use in the control of any one or more of appetite, feeding, food intake, energy expenditure and calorie intake. In particular, the invention provides the use of a peptide of the invention for the manufacture of a medicament for reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject.
The subject to whom the compound is administered may be overweight, for example, obese. Alternatively, or in addition, the subject may be diabetic, for example having insulin resistance or glucose intolerance, or both. The subject may have diabetes mellitus, for example, the subject may have Type II diabetes. The subject may be overweight, for example, obese and have diabetes mellitus, for example, Type II diabetes.
In addition, or alternatively, the subject may have, or may be at risk of having, a disorder in which obesity or being overweight is a risk factor. Such disorders include, but are not limited to, cardiovascular disease, for example hypertension, atherosclerosis, congestive heart failure, and dyslipidemia; stroke; gallbladder disease; osteoarthritis; sleep apnea; reproductive disorders for example, polycystic ovarian syndrome; cancers, for example breast, prostate, colon, endometrial, kidney, and esophagus cancer; varicose veins; acanthosis nigricans; eczema; exercise intolerance; insulin resistance; hypertension; hypercholesterolemia; cholithiasis; osteoarthritis; orthopedic injury; insulin resistance, for example, type 2 diabetes and syndrome X; metabolic syndrome; and thromboembolic disease (see Kopelman (2000), Nature 404:635-43; Rissanen et al., British Med. J. 301, 835, 1990).
Other disorders associated with obesity include depression, anxiety, panic attacks, migraine headaches, PMS, chronic pain states, fibromyalgia, insomnia, impulsivity, obsessive- compulsive disorder, irritable bowel syndrome (IBS), and myoclonus. Furthermore, obesity is a recognized risk factor for increased incidence of complications of general anesthesia. (See e.g., Kopelman, Nature 404:635-43, 2000). In general, obesity reduces life span and carries a serious risk of co-morbidities such as those listed above.
Other diseases or disorders associated with obesity are birth defects, maternal obesity being associated with increased incidence of neural tube defects, carpal tunnel syndrome (CTS); chronic venous insufficiency (CVI); daytime sleepiness; deep vein thrombosis (DVT); end stage renal disease (ESRD); gout; heat disorders; impaired immune response; impaired respiratory function; infertility; liver disease; lower back pain; obstetric and gynecologic complications; pancreatititis; as well as abdominal hernias; acanthosis nigricans; endocrine abnormalities; chronic hypoxia and hypercapnia; dermatological effects; elephantitis; gastroesophageal reflux; heel spurs; lower extremity edema; mammegaly which causes considerable problems such as bra strap pain, skin damage, cervical pain, chronic odors and infections in the skin folds under the breasts, etc.; large anterior abdominal wall masses, for example abdominal panniculitis with frequent panniculitis, impeding walking, causing frequent infections, odors, clothing difficulties, lower back pain; musculoskeletal disease; pseudo tumor cerebri (or benign intracranial hypertension), and sliding hiatil hernia.
Wynne et al (Intenational Journal of Obesity 12: 1729-1736, 2006) described how administering 400 nmoles of pre-prandial oxyntomodulin, three times daily for four days, increased activity-related energy expenditure by 143+/- 109 kcal/day or 26.2+/-9.9% (P=0.0221); total energy expenditure by 9.4+/-4.8% (P=0.0454) and physical activity level by 9.5+/-4.6% (P=0.0495). Accordingly, the present invention further provides a method for increasing energy expenditure in a subject. The method includes, for example, peripherally administering a therapeutically effective amount of a compound of the invention to the subject, thereby altering energy expenditure. Energy is burned in all physiological processes. The body can alter the rate of energy expenditure directly, by modulating the efficiency of those processes, or changing the number and nature of processes that are occurring. For example, during digestion the body expends energy moving food through the bowel, and digesting food, and within cells, the efficiency of cellular metabolism can be altered to produce more or less heat.
In one aspect the method of the invention involves manipulation of the arcuate circuitry that alter food intake coordinately, and reciprocally alter energy expenditure. Energy expenditure is a result of cellular metabolism, protein synthesis, metabolic rate, and calorie utilization. Thus, in this aspect of the invention, administration of a compound of the invention may result in increased energy expenditure, and decreased efficiency of calorie utilization. The invention also provides a method for improving a lipid profile in a subject. The invention also provides a method for alleviating a condition or disorder that can be alleviated by reducing nutrient availability.
Appetite can be measured by any means known to one of skill in the art. For example, decreased appetite can be assessed by a psychological assessment. For example, administration of a compound of the invention results in a change in perceived hunger, satiety, and/or fullness. Hunger can be assessed by any means known to one of skill in the art. For example, hunger is assessed using psychological assays, such as by an assessment of hunger feelings and sensory perception using a questionnaire, such as, but not limited to, a Visual Analog Score (VAS) questionnaire. In one specific, non-limiting example, hunger is assessed by answering questions relating to desire for food, drink, prospective food consumption, nausea, and perceptions relating to smell or taste.
A compound of the invention may be used for weight control and treatment, for example reduction or prevention of obesity, in particular any one or more of the following: preventing and reducing weight gain; inducing and promoting weight loss; and reducing obesity as measured by the Body Mass Index. A compound of the invention may be used in the control of any one or more of appetite, satiety and hunger, in particular any one or more of the following: reducing, suppressing and inhibiting appetite; inducing, increasing, enhancing and promoting satiety and sensations of satiety; and reducing, inhibiting and suppressing hunger and sensations of hunger. A compound of the invention may be used in maintaining any one or more of a desired body weight, a desired Body Mass Index, a desired appearance and good health.
A subject may be a subject who desires weight loss, for example female and male subjects who desire a change in their appearance. A subject may desire decreased feelings of hunger, for example the subject may be a person involved in a lengthy task that requires a high level of concentration, for example soldiers on active duty, air traffic controllers, or truck drivers on long distance routes, etc.
The present invention may also be used in treating, prevention, ameliorating or alleviating conditions or disorders caused by, complicated by, or aggravated by a relatively high nutrient availability. The term "condition or disorder which can be alleviated by reducing caloric (or nutrient) availability" is used herein to denote any condition or disorder in a subject that is either caused by, complicated by, or aggravated by a relatively high nutrient availability, or that can be alleviated by reducing nutrient availability, for example by decreasing food intake. Subjects who are insulin resistant, glucose intolerant, or have any form of diabetes mellitus, for example, type 1 , 2 or gestational diabetes, can also benefit from methods in accordance with the present invention.
Conditions or disorders associated with increased caloric intake include, but are not limited to, insulin resistance, glucose intolerance, obesity, diabetes, including type 2 diabetes; eating disorders, insulin-resistance syndromes, and Alzheimer's disease.
According to the present invention, a compound of the invention is preferably used in the treatment of a human. However, while the compounds of the invention will typically be used to treat human subjects they may also be used to treat similar or identical conditions in other vertebrates for example other primates; farm animals for example swine, cattle and poultry; sport animals for example horses; companion animals for example dogs and cats.
In summary, the invention also provides a peptide of the invention for use as a medicament for the prevention or treatment of obesity. There is also provided a peptide of the invention for use as a medicament for the prevention or treatment of diabetes or of a co-morbidity of obesity. Further, there is provided a peptide of the invention for use as a medicament for reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject.
The invention also provides a method of treating or preventing obesity in a subject in need thereof comprising administering to the subject a peptide according to the invention. There is also provided a method of treating or preventing diabetes or of a co-morbidity of obesity in a subject in need thereof comprising administering to the subject a peptide according to the invention. Further, there is provided a method of reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject in need thereof comprising administering to the subject a peptide according to the invention or a pharmaceutical composition according to the invention.
Compositions While it is possible for the active ingredient to be administered alone, it is preferable for it to be present in a pharmaceutical formulation or composition. Accordingly, the invention provides a pharmaceutical formulation comprising a compound of the invention, or a variant or derivative thereof, or a salt or solvate thereof, as defined above, and a pharmaceutically acceptable excipient. Pharmaceutical compositions of the invention may take the form of a pharmaceutical formulation as described below.
The pharmaceutical formulations according to the invention include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, and intraarticular), inhalation (including fine particle dusts or mists which may be generated by means of various types of metered doses, pressurized aerosols, nebulizers or insufflators, and including intranasally or via the lungs), rectal and topical (including dermal, transdermal, transmucosal, buccal, sublingual, and intraocular) administration, although the most suitable route may depend upon, for example, the condition and disorder of the recipient.
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with a pharmaceutical carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste. Various pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang, Y. J. and Hanson, M. A., Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S, 1988.
A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. The present compounds can, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release can be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. The compounds can be formulated, for administration orally, with delivery agents or carriers that facilitate the transport of therapeutic macromolecules and highly charged compounds across cell membranes, especially in the small intestine. Such delivery agents or carriers may in addition inhibit enzymatic degradation of peptides during passage through the gastrointestinal (GI) tract and/or the formulation may include additional agents that protect against such degradation. The present compounds can also be administered liposomally.
Exemplary compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The compounds of the invention can also be delivered through the oral cavity by sublingual and/or buccal administration. Moulded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used. Exemplary compositions include those formulating the present compound(s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG). Such formulations can also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g. Carbopol 934). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.
Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example saline or water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Exemplary compositions for parenteral administration include injectable solutions or suspensions which can contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid, or Cremaphor. An aqueous carrier may be, for example, an isotonic buffer solution at a pH of from about 3.0 to about 8.0, preferably at a pH of from about 3.5 to about 7.4, for example from 3.5 to 6.0, for example from 3.5 to about 5.0. Useful buffers include sodium citrate-citric acid and sodium phosphate-phosphoric acid, and sodium acetate/acetic acid buffers. The composition preferably does not include oxidizing agents and other compounds that are known to be deleterious to oxm and oxm agonists.
Excipients that can be included are, for instance, other proteins, such as human serum albumin or plasma preparations. If desired, the pharmaceutical composition may also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
Exemplary compositions for nasal aerosol or inhalation administration include solutions in saline, which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art. Conveniently in compositions for nasal aerosol or inhalation administration the compound of the invention is delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoro-methane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator can be formulated to contain a powder mix of the compound and a suitable powder base, for example lactose or starch. In one specific, non-limiting example, a compound of the invention is administered as an aerosol from a metered dose valve, through an aerosol adapter also known as an actuator. Optionally, a stabilizer is also included, and/or porous particles for deep lung delivery are included (e.g., see U.S. Patent No. 6,447,743). Intranasal formulations may include delivery agents for reversibly opening the nasal tight junction, thereby increasing drug permeability (e.g., see US Patent Application 10/322,266). Formulations for rectal administration may be presented as a retention enema or a suppository with the usual carriers such as cocoa butter, synthetic glyceride esters or polyethylene glycol. Such carriers are typically solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerine or sucrose and acacia. Exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).
Preferred unit dosage formulations are those containing an effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
The compounds of the invention are also suitably administered as sustained-release systems. Suitable examples of sustained-release systems of the invention include suitable polymeric materials, for example semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules; suitable hydrophobic materials, for example as an emulsion in an acceptable oil; or ion exchange resins; and sparingly soluble derivatives of the compound of the invention, for example, a sparingly soluble salt. Sustained-release systems may be administered orally; rectally; parenterally; intracistemally; intravaginally; intraperitoneally; topically, for example as a powder, ointment, gel, drop or transdermal patch; bucally; or as an oral or nasal spray.
Preparations for administration can be suitably formulated to give controlled release of compounds of the invention. For example, the pharmaceutical compositions may be in the form of particles comprising one or more of biodegradable polymers, polysaccharide jellifying and/or bioadhesive polymers, amphiphilic polymers, agents capable of modifying the interface properties of the particles of the compound of the invention. These compositions exhibit certain biocompatibility features which allow a controlled release of the active substance. See U.S. Patent No. 5,700,486. A compound of the invention may be delivered by way of a pump (see Langer, Science 249:1527-1533, 1990; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201, 1987; Buchwald et al., Surgery 88:507, 1980; Saudek et al., N. Engl. J. Med. 321 :574, 1989) or by a continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The key factor in selecting an appropriate dose is the result obtained, as measured by decreases in total body weight or ratio of fat to lean mass, or by other criteria for measuring control or prevention of obesity or prevention of obesity-related conditions, as are deemed appropriate by the practitioner. Other controlled release systems are discussed in the review by Langer, supra. In another aspect of the disclosure, compounds of the invention are delivered by way of an implanted pump, described, for example, in U.S. Patent No. 6,436,091; U.S. Patent No. 5,939,380; U.S. Patent No. 5,993,414.
Implantable drug infusion devices are used to provide patients with a constant and long term dosage or infusion of a drug or any other therapeutic agent. Essentially such device may be categorized as either active or passive. A compound of the present invention may be formulated as a depot preparation. Such a long acting depot formulation can be administered by implantation, for example subcutaneously or intramuscularly; or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials, for example as an emulsion in an acceptable oil; or ion exchange resins; or as a sparingly soluble derivatives, for example, as a sparingly soluble salt.
A therapeutically effective amount of a compound of the invention may be administered as a single pulse dose, as a bolus dose, or as pulse doses administered over time. Thus, in pulse doses, a bolus administration of a compound of the invention is provided, followed by a time period wherein a compound of the invention is administered to the subject, followed by a second bolus administration. In specific, non-limiting examples, pulse doses of a compound of the invention are administered during the course of a day, during the course of a week, or during the course of a month.
In one embodiment, a therapeutically effective amount of a compound of the invention is administered with a therapeutically effective amount of another agent, for example an additional appetite suppressant, a food-intake-reducing, dipetidyl peptidase-FV (DPP-IV) inhibiting, plasma glucose-lowering or plasma lipid-altering agent. Specific, non-limiting examples of an additional appetite suppressant include amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine, fenfluramine, dexfenfluramine, sibutramine, rimonabant, and fluoxetine. Specific, non-limiting examples of DPP-IV inhibitors include Januvia (sitagliptin phosphate), and Galvus (vildagliptin). The compound of the invention can be administered simultaneously with the additional agent, or it may be administered sequentially. Thus, in one embodiment, the compound of the invention is formulated and administered with an additional agent as a single dose.
In another embodiment, a therapeutically effective amount of a compound of the invention is administered in combination with a therapeutically effective amount of another agent, for the treatment of diseases other than obesity, for example diabetes, in which specific non limiting examples of an additional therapeutic agent are GLP-I or an analogue thereof, exenatide, and pramlintide.
A compound of the invention may be administered whenever the effect, e.g., appetite suppression, decreased food intake, or decreased caloric intake, is desired, or slightly before to whenever the effect is desired, such as, but not limited to about 10 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, about 120 minutes, about 4 hours, about 8 hours, or about 12 hours, before the time the effect is desired.
A compound of the invention may be administered in combination with whenever the effect, e.g., appetite suppression, decreased food intake, or decreased caloric intake, is desired, or slightly before to whenever the effect is desired, such as, but not limited to about 10 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, about 120 minutes, about 4 hours, about 8 hours, or about 12 hours, before the time the effect is desired.
Dosages
The therapeutically effective amount of a compound of the invention will be dependent on the molecule utilized, the subject being treated, the severity and type of the affliction, and the manner and route of administration. For example, a therapeutically effective amount of a compound of the invention may vary from about 0.01 μg per kilogram (kg) body weight to about 1 g per kg body weight, for example about .0.1 μg to about 5 mg per kg body weight, or about 1 μg to about 1 mg per kg body weight per day. A compound of the invention may be administered to a subject at 0.5 to 200 picomole (pmol) per kg body weight, or about 20 pmol per kg body weight. For especially active compounds or compounds administered by an especially efficient route, in one specific, non-limiting example, a compound of the invention is administered in a dose of about 1 nmol or more, 2 nmol or more, 5 nmol or more, or 10 nmol or more and the dose of the compound of the invention is generally not more than 100 nmol, for example, the dose is 90 nmols or less, 80 nmols or less, 70 nmols or less, 60 nmols or less, 50 nmols or less, 40 nmols or less, 30 nmols or less, 20 nmols or less, or 10 nmols or less. For a less active compound or a compound administered by a less efficient route, in another specific, non-limiting example, a compound of the invention is administered in a dose of about 100 nmol or more, 200 nmol or more, 300 nmol or more, 400 nmol or more, 500 nmol or more, 600 nmol or more, 700 nmol or more, 800 nmol or more, 900 nmol or more, or
1 μmol or more and the dose of the compound of the invention is generally not more than 10 μmols, for example, the dose is 9 μmols or less, 8 μmols or less, 7 μmols or less, 6 μmols or less, 5 μmols or less, 4 μmols or less, 3 μmols or less, 2 μmols or less, 1 μmol or less. For example, a dosage range may comprise any combination of any of the specified lower dose limits with any of the specified upper dose limits. Thus, examples of non-limiting dose ranges of compounds of the invention are within the range of from 1 nmol to 1 μmol, from 1 to 900 nmols, or from 1 to 800 nmols. For especially active compounds or compounds administered by an especially efficient route, the dose may be from 1 nmol to 100 nmol, from
2 to 80 nmols, or from 5 to 60 nmols. For a less active compound or a compound administered by a less efficient route, the dose may be from 100 nmol to 10 μmol, from 200 nmol to 5 μmols, or from 500 nmols to 2 μmols.
In one specific, non-limiting example, from about 0.5 to about 50 nmol of a compound of the invention is administered, for example about 1 to about 20 nmol, for example, about 2 nmol is administered as a subcutaneous injection. The exact dose is readily determined by one of skill in the art based on the potency of the specific compound utilized, the age, weight, sex and physiological condition of the subject.
In another specific non-limiting example, a compound of the invention is administered to a subject in a dose of about 1 μg to about 2 mg per dose, about once, about twice, about three times, or about four times per day., A therapeutically effective amount of a compound of the invention may vary from about 0.01 μg per kilogram (kg) body weight to about 1 g per kg body weight, for example about 0.1 μg to about 5 mg per kg body weight, or about 5 μg to about 1 mg per kg body weight per day. Bearing in mind that a typical oxyntomudilin analogue of the invention has a molecular weight of around 4500, a compound of the invention may be administered to a subject at 2.25 to 900 ng per kg body weight, or about 90 ng per kg body weight. For especially active compounds or compounds administered by an especially efficient route, in one specific, non-limiting example, a compound of the invention is administered in a dose of about 4.5 μg or more, 9 μg or more, 22.5 μg or more, or 45 μg or more and the dose of the compound of the invention is generally not more than 450 μg, for example, the dose is 405 μg or less, 360 μg or less, 315 μg or less, 270 μg or less, 225 μg or less, 180 μg or less, 135 μg or less, 90 μg or less, or 45 μg or less. For a less active compound or a compound administered by a less efficient route, in another specific, non- limiting example, a compound of the invention is administered in a dose of about 450 μg or more, 900 μg or more, 1350 μg or more, 1800 μg or more, 2250 μg or more, 2700 μg or more, 3150 μg or more, 3600 μg or more, 4050 μg or more, or 4500 μg or more and the dose of the compound of the invention is generally not more than 45000 μg , for example, the dose is 40500 μg or less, 36000 μg or less, 31500 μg or less, 27000 μg or less, 22500 μg or less, 18000 μg or less, 13500 μg or less, 9000 μg or less, 45000 μg or less. For example, a dosage range may comprise any combination of any of the specified lower dose limits with any of the specified upper dose limits. Thus, examples of non-limiting dose ranges of compounds of the invention are within the range of from 4.5 μg to 4500 μg, from 4.5 to 4050 μg , or from 4.5 to 3600 μg. For especially active compounds or compounds administered by an especially efficient route, the dose may be from 4.5 μg to 450 μg, from 9 to 360 μg, or from 22.5 to 270 μg. For a less active compound or a compound administered by a less efficient route, the dose may be from 450 μg to 45000 μg, from 900 μg to 22500 μg, or from 2250 to 9000 μg.
Suitable doses of compounds of the invention also include those that result in a reduction in calorie intake, food intake, or appetite, or increase in energy expenditure that is equivalent to the reduction in calorie intake, food intake, or appetite, or to increase the energy expenditure, caused by levels of oxm that have been observed in man. Examples of doses include, but are not limited to doses that produce the effect demonstrated when the serum levels of oxm are from about 800 pM to about 1300 pM, or from about 900 pM to about 1000 pM, or about 950 pM.
Suitable doses of compounds of the invention also include those that are equivalent to levels of oxm seen in subjects experiencing conditions associated with reduced appetite, for example jejunoileal bypass (Sarson et al, IntJObes, 1981, 5:471-480; Hoist et ai, ScandJ Gastroenterol, 1979, 14:205-207).
In a study of the effects of oxyntomodulin on appetite suppression and food intake reduction in humans (Cohen et al, J. Clin. Endocrinol. Metab., 2003, 88(10), 4696-4701) it was found that an infusion of oxyntomodulin to human volunteers at 3.0 pmol/kg.min for 90 minutes led to a significantly reduced ad libitum energy intake (19.3 +/- 5.6%; P<0.01). The total oxyntomodulin infused was 270 pmol/kg body weight. The observed oxyntomodulin-like immunoreactivity in the blood of the subjects rose to around 800 pmol/L during the infusion. In a study of the effects of oxyntomodulin on weight loss in humans (Wynne et al, Diabetes., 2005, 54(Aug), 2390-2395) it was found that subcutaneous injections of oxyntomodulin to humans volunteers resulted in a significant reduction of body weight. Over the study period of 28 days, body weight of the treatment group was reduced by 2.3 ± 0.4 kg in the treatment group compared with 0.5 ± 0.5 kg in the control group (P = 0.0106). 1.8 mg (approximately 400 nmol) of oxyntomodulin was administered three times daily 30 mins before meals. On average, the treatment group had an additional 0.45kg weight loss per week. Energy intake by the treatment group was significantly reduced by 170 ± 37 kcal (25 ± 5%) at the initial study meal within the 28 day study period (P = 0.0007) and by 250 ± 63 kcal (35 ± 9%) at the final study meal during the 28 day study period (P = 0.0023), with no change in subjective food palatability. Oxyntomodulin treatment resulted in weight loss and a change in the levels of adipose hormones consistent with a loss of adipose tissue. The anorectic effect was maintained over the 4-week period.
The compounds of the invention have been found to be more active and/or longer-lasting than native oxyntomodulin as used in human studies to date (Cohen et al (2003) and Wynne et al. (2005) Diabetes 54(Aug), 2390-2395). The dosage required for a compound of the invention may be somewhat lower than that required for native oxyntomodulin. The dosages of peptides of the invention required to observe an effect in humans can be expected to be a lower, for example 2.5 times, 200 times, 400 times, and 1-4000 times lower than the dose of native oxyntomodulin. The magnitude of the potency of the peptides of the invention in comparison to the native oxyntomodulin peptide may also allow the frequency of administration a compound of the invention to be lower than that required for native oxyntomodulin.
The disclosure is illustrated by the following non-limiting Examples.
EXAMPLES Materials and Methods Animals: All animal procedures were approved by the British Home Office Animals (Scientific Procedures) Act 1986 (Project License number 70/5516). Male C57BL/6 mice and male Wistar rats were maintained in individual cages under controlled temperature (21 -23 0C) with ad libitum access to standard chow (RMl diet, SDS Ltd, Witham, Essex, UK) and to water. The light cycle was 12 hours light and 12 hours dark with 'dawn' at 07:00, lights fullon at 07:30, 'dusk' at 19:00 with lights off at 19:30. These times were fixed in the animal facility. All animals were handled almost daily for on average nine days prior to the first study. During the acclimatization period, mice received two saline injections at least two days apart in order to further acclimatize to the procedure on the study days. It was found in rats that minimising the number of injections provided an optimal response, and so acclimatization injections were not used.
Intra-peritoneal (IP) injections: IP injections were administered to mice via a 0.5 ml syringe with a 29-gauge needle (maximum injection volume 0.1 ml). The maximum volume administered IP was 0.1 ml.
Subcutaneous (SC) injections: SC injections were administered to rats via a 0.5 ml syringe with a 29-gauge needle (maximum injection volume 0.2 ml), in a volume of 0.1 ml if administered to the thigh skin, or 0.2 ml if administered to the neck scruff.
Study protocol: C57BL/6 mice (20-35 g) were injected with the peptide under investigation following a 20-hour fast. Wistar rats were injected following a 24-hour fast. Typically 6 to
10 rodents were used per experimental group. Injections were typically administered at 9:00.
A pre-weighed quantity of chow was presented immediately after injection. The remaining food was measured at regular time intervals (e.g. 1, 2, 3,4, 6, 8, 24, 32 and 48 hours following injection) and food intake calculated.
Peptides Synthesis
Synthesis of peptides
Peptides were produced by solid phase step-wise synthesis (SPSS) using the Fmoc N-terminal protection strategy. Chain assembly was performed on Applied Biosystems 431, 433 or Pioneer automated synthesisers. Solid phase resins were used with factory pre-loaded C terminal amino acid or with an amide linker as appropriate. The following side-chain protecting groups were used: Asn(Trt), Gln(Trt), Cys(Trt), His(Trt), Asp(tBu), Glu(tBu),
Ser(tBu), Thr(tBu), Tyr(tBu), Arg(Pbf), Lys(Boc), Trp(Boc). In some cases, where synthesis difficulty was anticipated, pre-formed oxazolidine dipeptides were used in place of respective monomers. All chemicals (from various suppliers including Applied Biosystems, Merck Biosciences and AGCT) were synthesis grade. Feedback monitoring to optimise syntheses was employed on all instruments.
Recovery of peptides After synthesis, peptides were cleaved from the solid phase resin support and fully side chain deprotected. This was achieved by treatment for 2 hours with trifluoroacetic acid (TFA) containing 4% water and 2.5% tri-isopropylsilane to scavenge side-chain protecting groups. Peptide-TFA solutions were filtered from the resins and the peptides precipitated with methyl tertiary butyl ether (MTBE). Peptides were isolated by centrifugation, washed in MTBE and dried under vacuum.
Analysis and purification of peptides
Peptides were dissolved in de-ionized water, with addition of acetic acid where necessary. Peptide solutions were clarified by centrifugation or filtration (Whatman GD/X syringe filter) prior to analysis and purification.
All peptide products were analysed by reverse phase HPLC on an Applied Biosystems BioCad instrument using an analytical Brownlee Aquapore RP300 C8 or Phenomenex Synergi Hydro Cl 8 column. Purification was performed by reverse phase HPLC using preparative columns of the above types. Acetonitrile-water gradients (with TFA as counter- ion) were used for elution of products. Capillary Zone Electrophoresis (CZE) was performed on crude and purified peptides using a Hewlett Packard 3DCE instrument. Molecular weight determination was performed on a Micromass MALDI -R mass spectrometer.
Purified peptides were freeze-dried in pharmaceutical grade glass vials (Adelphi Vials) and closed under vacuum.
Derivatised side chains Peptides having side chains derivatised with an acyl or alkyl group were prepared by standard methods.
Solubility of derivatised peptides
Derivatised polypeptides should be fully dissolved before administration. In order to achieve solubility it may be necessary to dissolve the polypeptides in a small amount of dilute alkali (for example, 50 μl 0.01 NaOH) and then dilute the dissolved peptide in saline.
Inhibition of food intake experiments.
Example 1 (comparative example). The feeding effect of native oxyntomodulin (human) was investigated by intraperitoneal injection of 1400 nmoles/kg to groups of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 2. Due to the relatively low activity of native oxyntomodulin, a high dose was given. Less significant results are observed with lower doses.
Example 2 (comparative example).
The feeding effect of native oxyntomodulin (human) was investigated by subcutaneous injection of 1400 nmoles/kg to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 6 hours is shown in comparison to saline in Figure 3. It can be seen that even at a high dose of 1400 nmol/kg, native oxyntomodulin is not capable of reducing food intake in fasted rats under these conditions. At lower doses, the same lack of effectiveness is observed.
Example 3.
The feeding effects of the following analogues of oxyntomodulin were investigated: PEPTIDE NO: 178 [SEQ.ID NO: 178]; PEPTIDE NO: 82 [SEQ ID NO:82]; PEPTIDE NO: 58 [SEQ ID NO:58]; and PEPTIDE NO: 52 [SEQ ID NO:52]. The analogues were administered at a dose of 10 (PEPTIDE NO: 178 [SEQ ID NO:178]) and 10 (PEPTIDE NO: 82 [SEQ ID NO:82]; PEPTIDE NO: 58 [SEQ ID NO:58]; and PEPTIDE NO: 52 [SEQ ID NO:52]) nmoles/kg by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 4 to 7. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 4. The feeding effects of the following analogues of oxyntomodulin were investigated:
PEPTIDE NO: 164 [SEQ ID NO:164]; and PEPTIDE NO: 167 [SEQ ID NO: 167]. The analogues were administered at a dose of 4 and 5 nmoles/kg respectively, by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 48 hours (PEPTIDE NO: 164 [SEQ ID NO: 164]) and 32 hours (PEPTIDE NO: 167 [SEQ ID NO: 167]) is shown in comparison to saline in Figures 8 and 9. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 48 (PEPTIDE NO: 164 [SEQ ID NO: 164]) and 32 (PEPTIDE NO: 167 [SEQ ID NO: 167]) hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 24 hours (PEPTIDE NO: 164 [SEQ ID NO: 164]) or 8 hours (PEPTIDE NO: 167 [SEQ ID NO: 167]). It is also lower than in the control group treated with native oxyntomodulin.
Example 5.
The feeding effects of the following analogues of oxyntomodulin were investigated:
PEPTIDE NO: 100 [SEQ ID NO: 100]; and PEPTIDE NO: 148 [SEQ ID NO: 148]. The analogues were administered at a dose of 20 and 10 nmoles/kg respectively, by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 10 and 11. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 6. The feeding effects of the following analogues of oxyntomodulin were investigated:
PEPTIDE NO: 60 [SEQ ID NO:60]; and PEPTIDE NO: 94 [SEQ ID NO:94]. The analogues were administered at a dose of 100 and 5 nmoles/kg respectively, by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 12 and 13. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 7.
The feeding effects of the following analogue of oxyntomodulin was investigated: PEPTIDE NO: 155 [SEQ ID NO: 155]. The analogue was administered at a dose of 4 nmoles/kg by subcutaneous injection to a group of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 32 hours is shown in comparison to saline in Figure 14. The analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 32 hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 8 hours. It is also lower than in the control group treated with native oxyntomodulin.
Example 8. The feeding effects of the following analogues of oxyntomodulin were investigated:
PEPTIDE NO: 142 [SEQ ID NO: 142]; PEPTIDE NO: 184 [SEQ ID NO: 184]; and PEPTIDE NO: 172 [SEQ ID NO: 172]. The analogues were administered at a dose of 3 nmoles/kg by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 15 to 17. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 9.
The feeding effects of the following analogues of oxyntomodulin were investigated: PEPTIDE NO: 4 [SEQ ID NO:4]; PEPTIDE NO: 195 [SEQ ID NO:195]; PEPTIDE NO: 136 [SEQ ID NO:136]; and PEPTIDE NO: 108 [SEQ ID NO: 108]. The analogues were administered at doses of 5, 800, 5 and 100 nmoles/kg respectively, by intraperitoneal injection to groups of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 18 to 21. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 10. The feeding effects of the following analogues of oxyntomodulin were investigated:
PEPTIDE NO: 142 [SEQ ID NO: 142]; PEPTIDE NO: 22 [SEQ ID NO:22]; PEPTIDE NO: 153 [SEQ ID NO: 153]; and PEPTIDE NO: 199 [SEQ ID NO: 199]. The analogues were administered at a dose of 3 nmoles/kg, 200 nmoles/kg (PEPTIDE NO: 153 [SEQ ID NO: 153]), and 500 nmoles/kg (PEPTIDE NO: 199 [SEQ ID NO: 199]) by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figures 22 to 25. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 11.
The feeding effects of the following analogues of oxyntomodulin were investigated: PEPTIDE NO: 210 [SEQ ID NO:210]; PEPTIDE NO: 211 [SEQ ID NO:211]; PEPTIDE NO: 213 [SEQ ID NO:213]; and PEPTIDE NO: 214 [SEQ ID NO:214]. The analogues were administered at a dose of 20, 200, 400 and 400 nmoles/kg respectively by intraperitoneal injection to groups of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 48 hours is shown in comparison to saline in Figures 26 to 29. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 48 hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 24 hours. It is also lower than in the control group treated with native oxyntomodulin.
Example 12. The feeding effects of the following analogues of oxyntomodulin were investigated:
PEPTIDE NO: 201 [SEQ ID NO:201]; and PEPTIDE NO: 202 [SEQ ID NO:202]. The analogues were administered at a dose of 5 nmoles/kg by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 48 hours is shown in comparison to saline in Figures 30 and 31. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 48 hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 24 hours. It is also lower than in the control group treated with native oxyntomodulin.
Example 13.
The feeding effect of the following analogue of oxyntomodulin was investigated: PEPTIDE NO: 203 [SEQ ID NO:203]. The analogue was administered at a dose of 100 nmoles/kg by subcutaneous injection to a group of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 32. The analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 14.
The feeding effects of the following analogues of oxyntomodulin were investigated: PEPTIDE NO: 204 [SEQ ID NO:204]; and PEPTIDE NO: 205 [SEQ ID NO:205]. The analogues were administered at a dose of 5 nmoles/kg by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 32 hours is shown in comparison to saline in Figures 33 and 34. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 32 hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 8 hours. It is also lower than in the control group treated with native oxyntomodulin.
Example 15.
The feeding effects of the following analogues of oxyntomodulin were investigated:
PEPTIDE NO: 206 [SEQ ID NO:206]; PEPTIDE NO: 207 [SEQ ID NO:207]and PEPTIDE NO: 209 [SEQ ID NO:209]. The analogues were administered at a dose of 80 nmoles/kg by subcutaneous injection to groups of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 48 hours is shown in comparison to saline in Figures 35 to 37. The analogues demonstrate a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 48 hour period; that is to say that the food intake over the first 24 hour period is lower than in the saline control and continues to remain below it in the following 24 hours. It is also lower than in the control group treated with native oxyntomodulin.
Example 16. The feeding effect of the following analogue of oxyntomodulin was investigated: PEPTIDE NO: 215 [SEQ ID NO:215]. The analogue was administered at a dose of 5 nmoles/kg by subcutaneous injection to a group of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 38. The analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 17. The feeding effect of the following analogue of oxyntomodulin was investigated: PEPTIDE NO: 216 [SEQ ID NO:216]. The analogue was administered at a dose of 10 nmoles/kg by subcutaneous injection to a group of fasted rats. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 39. The analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 18.
The feeding effect of the following analogue of oxyntomodulin was investigated: PEPTIDE NO: 355 [SEQ ID NO:355]. The analogue was administered at a dose of 5 nmoles/kg by subcutaneous injection to a group of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 4 hours is shown in comparison to saline in Figure 40. The analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 4 hour period; that is to say that the food intake over the 4 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin.
Example 19.
The feeding effect of the following analogue of oxyntomodulin was investigated: PEPTIDE NO: 130 [SEQ ID NO: 130]. The analogue was administered at a dose of 20 nmoles/kg by subcutaneous injection to a group of fasted mice. A further group was administered saline (control). Mean cumulative food intake over the course of 24 hours is shown in comparison to saline in Figure 41. The analogue demonstrates a potent and long acting suppression of food intake in comparison to the saline control. The food intake suppression continues for the whole 24 hour period; that is to say that the food intake over the 24 hour period is lower than in the saline control. It is also lower than in the control group treated with native oxyntomodulin. It will be appreciated that throughout the above examples, compounds of the invention are capable of inhibiting food intake at doses markedly lower than that of the native peptide used in the comparator experiments.

Claims

Claims
1. A peptide comprising the amino acid sequence:
Xaal Xaa2 Xaa3 Gly4 Thr5 Phe6 Thr7 Ser8 Asp9 TyrlO Serl 1 Lysl2 Tyrl3 Leul4
Xaal5 Xaal6 Xaal7 Xaal8 Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Tφ25 Leu26 Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 Lys33 Asn34 Asn35 Ile36 Ala37; wherein:
Xaal is Hisl or D-Hisl, Xaa2 is Ser2 or Ala2,
Xaa3 is Gln3 or Asp3;
Xaal5 Xaalό Xaal7 Xaal8 Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is: GIu 15 Glul 6 GIu 17 Leu 18 VaI 19 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glul5 Glulό Glul7 Leul8 VaIl 9 Lys20 Tyr21 Phe22 Leu23 Gln24, GIu 15 Glulό GIu 17 Leu 18 VaI 19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glulό Glul7 Leul8 VaIl 9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glulό Glul7 Del 8 VaIl 9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glulό Glul 7 Del 8 VaIl 9 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glul 5 Glulό Glul 7 Del 8 VaIl 9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul 5 Glulό Glul 7 Del 8 VaIl 9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul 5 Glnlό Glul 7 Leul8 VaI 19 Lys20 Tyr21 Phe22 Leu23 Glu24, GIu 15 Glnlό GIu 17 Leu 18 VaI 19 Lys20 Tyr21 Phe22 Leu23 Gln24, GIu 15 Glnl 6 GIu 17 Leu 18 VaI 19 Lys20 Tyr21 Phe22 Ile23 Glu24,
Glul 5 Glnl 6 Glul 7 Leul 8 VaIl 9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul 5 Glnl 6 Glul 7 Uel8 VaIl 9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul 5 Glnl 6 Glul 7 Ilel8 VaIl 9 Lys20 Tyr21 Phe22 Leu23 Gln24, GIu 15 Glnl 6 GIu 17 He 18 VaI 19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul 5 Glnl 6 Glul 7 Ilel8 VaIl 9 Lys20 Tyr21 Phe22 Ile23 Gln24, or Aspl5 Serlό Argl7 Argl8 Alal9 Gln20 Asp21 Phe22 Val23 Gln24;
Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is: Met27 Asn28 Thr29 Lys30 Arg31 Asn32,
Lys27 Asn28 Ala29 Gly30 Pro31 Ser32, or Lys27 Asn28 Gly29 Gly30 Pro31 Ser32 or a peptide as set out above in which residue Asn34 is replaced with Asp34; or a peptide as set out above in which Xaa3 is Glu3; with the proviso that if
Xaal 5 Xaalό Xaal 7 Xaal 8 Xaal 9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is Aspl5 Serlό Argl7 Argl8 Alal9 Gln20 Asp21 Phe22 Val23 Gln24, then Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is not Met27 Asn28 Thr29 Lys30 Arg31 Asn32 (SEQ ID NO: 356).
2. A peptide as claimed in claim 1, wherein Xaal5 Xaalό Xaal7 Xaalδ Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
Glul5 Glulό Glul7 Leulδ Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glulό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glulό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glulό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glulό Glul7 Ilel8 VaI 19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glulό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, Glul5 Glnlό Glul7 Leul8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24, Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Glu24, Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Glu24, or Glul5 Glnlό Glul7 Ilel8 Vall9 Lys20 Tyr21 Phe22 Ile23 Gln24
(SEQ ID NO: 359).
3. A peptide as claimed in any of claims 1 to 2, wherein
Xaal Xaa2 Xaa3 is Hisl Ser2 Gln3, or.
D-His 1 Ser2 Gln3, or D-Hisl Ala2 Gln3, or D-His 1 Ala2 Asp3 (SEQ ID NO: 360).
4. A peptide as claimed in any of claims 1 to 3, wherein
Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
Lys27 Asn28 Ala29 Gly30 Pro31 Ser32, or Lys27 Asn28 Gly29 Gly30 Pro31 Ser32
(SEQ ID NO: 361).
5. A peptide as claimed in claim 1 having an amino acid sequence selected from the group consisting of:
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID
NO: 1)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 2) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 3)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 4) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys
Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 5)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ YD
NO: 6)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 7)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 8)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 9 His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys
Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 10)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO:
H)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ HD NO: 12)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 13)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 14) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys
Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 15) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 16) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys
Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 17)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID
NO: 18)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 19)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ JD NO: 20)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 21) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys
Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO:
22)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO:
23)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ JD NO: 24)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 25)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ JD NO: 26) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys
Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 27)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ JD
NO: 28)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ JD NO: 29) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 30)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 31) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys
Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO:
32)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID
NO: 33)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 34)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 35)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ E) NO: 36) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys
Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 37)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ E)
NO: 38)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 39)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 40)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 41) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys
Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 42) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 43) His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys
Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 44)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID
NO: 45)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 46)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ H) NO: 47)
His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ E) NO: 48) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 49)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 50)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 51)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 52)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 53) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 54)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 55)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 56) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 57)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 58) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 59
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 60
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 61
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI *Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 62)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 63) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 64)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Tip Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 65)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 66)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 67)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 68) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 69) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu lie VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 70) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 71)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 72)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 73)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 74)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 75) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 76)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 77)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 78)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 79)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 80) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 81)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 82)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 83) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 84)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu lie VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 85) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 86)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 87)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 88)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 89)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ HD NO: 90) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 91)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ H)
NO: 92)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 93)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 94)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 95) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 96) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 97) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 98)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 99)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 100)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 101)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ HD NO: 102) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 103)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 104)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 105)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ JD NO: 106)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 107) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 108)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 109)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 1 10) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 111)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 112) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 113)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ED NO: 114)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 115)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 116)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 117) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 118)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 119)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 120)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 121)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 122) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIu Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 123) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 124) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 125)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 126)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 127)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 128)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 129) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 130)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 131)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 132)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 133)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 134) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 135)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 136)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 137) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 138)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu lie VaI Lys Tyr Phe Ue GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 139) D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 140)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ED NO: 141)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ TD NO: 142)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 143)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 144) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 145)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 146)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ H) NO: 147)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 148)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 149) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 150) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe lie GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 151) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 152)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 153)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 154)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 155)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 156) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 157)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 158)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 159)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 160)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 161) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 162)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 163)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 164) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 165)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu lie VaI Lys Tyr Phe lie GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 166) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 167)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 168)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn Ue Ala (SEQ ID NO: 169)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 170)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 171) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 172)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 173)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 174)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 175)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 176) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 177) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 178) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ED NO: 179)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ
ID NO: 180)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 181)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 182)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 183) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 184)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 185)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 186)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 187)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 188) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 189)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 190)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ LD NO: 191) D-HisAla Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 192)
6. A peptide as claimed in any one of claims 1 to 5, wherein the peptide has an additional extension moiety of sequence -A-B-C, wherein:
A is absent or 1, 2, 3 or 4 Ala residues or 1, 2, 3 or 4 GIu residues
B is absent or 1 , 2, 3 or 4 Ala residues or 1 , 2, 3 or 4 GIu residues
provided that A and B do not both comprise Ala residues, and that A and B do not both comprise GIu residues; and
C is Lys, or Lys with an acid selected from capric acid, lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid, attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
7. A peptide as claimed in claim 6, wherein A or B or both A and B are absent.
8. A peptide as claimed in claim 6, wherein A is one GIu residue, and B is one Ala residue.
9. A peptide as claimed in any of claims 6 to 8, wherein C is a Lys residue.
10. A peptide as claimed in any of claims 6 to 8, wherein:
- C is a Lys residue with lauric acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond. - C is a Lys residue with myristic acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
- C is a Lys residue with palmitic acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
-C is a Lys residue with stearic acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
- C is a Lys residue with arachidic acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
- C is a Lys residue with capric acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
11. A peptide according to claim 6 having a structure sequence selected from the group consisting of: D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 201)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys
(SEQ ID NO: 202)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala Lys (SEQ ID NO: 203)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 204)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 205) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-myristoyl (SEQ HD NO: 206)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala
Lys-palmitoyl (SEQ H) NO: 207)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-stearoyl (SEQ ID NO: 208)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-arachidoyl (SEQ ID NO: 209)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys (SEQ ID NO: 210) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-myristoyl (SEQ ID NO: 211)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala
Lys-myristoyl (SEQ ID NO: 212) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-palmitoyl (SEQ ID NO: 213) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-arachidoyl (SEQ ID NO: 214)
12. A peptide according to claim 1 having a structure sequence selected from the group consisting of:
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 215)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 216)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn lie Ala (SEQ ID NO: 217)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ
ID NO: 218)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ HD NO: 219)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 220)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 221) D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Tip Leu Met Asn Thr Lys Arg Asn Lys Asp Asn He Ala (SEQ ID NO: 222)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 223)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID
NO: 224)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 225)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asp Asn He Ala (SEQ ID NO: 226)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 227)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 228)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ
ID NO: 229)
D-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 230) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 231)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asp Asn He Ala (SEQ ID NO: 232)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ ID
NO: 233)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 234)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 235)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 236)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 237)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ
ID NO: 238)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 239) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 240)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Lys (SEQ JD NO: 241)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Lys
(SEQ ID NO: 242)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asp Asn He Ala Lys (SEQ JD NO: 243)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Lys (SEQ ID NO: 244)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Lys (SEQ JD NO: 245)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Ala Ala Lys-myristoyl (SEQ JD NO: 246)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Ala Ala
Lys-palmitoyl (SEQ ID NO: 247)
D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Ala Ala Lys-stearoyl (SEQ ID NO: 248) D-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Ala Ala Lys-arachidoyl (SEQ ID NO: 249)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala GIu Ala Lys (SEQ ID NO: 250)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala GIu Ala
Lys-myristoyl (SEQ ID NO: 251)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala GIu Ala Lys-palmitoyl (SEQ E) NO: 252)
D-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala GIu Ala Lys-arachidoyl (SEQ ID NO: 253)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 254)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ K) NO: 255)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ
ID NO: 256)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 257) L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn lie Ala (SEQ ID NO: 258)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 259)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID
NO: 260)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asp Asn He Ala (SEQ ID NO: 261)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 262)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ED NO: 263)
L-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 264)
L-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asp Asn He Ala (SEQ
ID NO: 265)
L-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Tip Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 266) L-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 267)
L-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu lie VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 268)
L-His Ala GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Ue GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID
NO: 269)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 270)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIu Trp Leu Met Asn Thr Lys Arg Asn Lys Asp Asn He Ala (SEQ ID NO: 271)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 272)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 273)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala (SEQ ID
NO: 274)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 275) L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 276)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 277)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ
ID NO: 278)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala (SEQ ID NO: 279)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Lys (SEQ ID NO: 280)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Lys (SEQ ID NO: 281)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asp Asn He Ala Lys (SEQ ID NO: 282)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Lys
(SEQ ID NO: 283)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Lys (SEQ ID NO: 284) L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Ala Ala Lys-myristoyl (SEQ ID NO: 285)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Ala Ala Lys-palmitoyl (SEQ ID NO: 286)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Ala Ala
Lys-stearoyl (SEQ ID NO: 287)
L-His Ala Asp GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asp Asn He Ala Ala Ala Lys-arachidoyl (SEQ ID NO: 288)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala GIu Ala Lys (SEQ ED NO: 289)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala GIu Ala Lys-myristoyl (SEQ ID NO: 290)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala GIu Ala Lys-palmitoyl (SEQ DD NO: 291)
L-His Ser GIn GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asp Asn He Ala GIu Ala
Lys-arachidoyl (SEQ ID NO: 292)
13. A peptide according to claim 1 having a structure sequence selected from the group comprising: D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu lie VaI Lys Tyr Phe lie GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ TD NO: 293)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn lie Ala (SEQ ID NO: 294)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 295)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn Ue Ala (SEQ ID NO: 296)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 297)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 298)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 299)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 300)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 301) D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe lie GIn Tip Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 302)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 303)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 304)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 305)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 306)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 307)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 308)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 309)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 310) D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Tip Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ H) NO: 311)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 312)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala Lys
(SEQ E) NO: 313)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 314)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 315)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-myristoyl (SEQ ED NO: 316)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-palmitoyl (SEQ ID NO: 317)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala
Lys-stearoyl (SEQ ID NO: 318)
D-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-arachidoyl (SEQ ID NO: 319) D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys (SEQ ID NO: 320)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-myristoyl (SEQ ID NO: 321)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala
Lys-palmitoyl (SEQ ID NO: 322)
D-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-arachidoyl (SEQ HD NO: 323)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ YD NO: 324)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIu Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 325)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIu Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 326)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID
NO: 327)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 328) L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe lie GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ID NO: 329)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E) NO: 330)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ E)
NO: 331)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 332)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala (SEQ ED NO: 333)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 334)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 335)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 336)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 337) L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Tip Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 338)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 339)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ
ID NO: 340)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala GIn Asp Phe VaI GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala (SEQ ID NO: 341)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 342)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu He VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ ID NO: 343)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu He VaI
Lys Tyr Phe He GIn Trp Leu Met Asn Thr Lys Arg Asn Lys Asn Asn He Ala Lys (SEQ HD NO: 344)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys
(SEQ ID NO: 345)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIn GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Lys (SEQ H) NO: 346) L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Tip Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-myristoyl (SEQ K) NO: 347)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn lie Ala Ala Ala Lys-palmitoyl (SEQ ID NO: 348)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala
Lys-stearoyl (SEQ ID NO: 349)
L-His Ala GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe He GIn Trp Leu Lys Asn GIy GIy Pro Ser Lys Asn Asn He Ala Ala Ala Lys-arachidoyl (SEQ ID NO: 350)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys (SEQ ID NO: 351)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-myristoyl (SEQ HD NO: 352)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI
Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala Lys-palmitoyl (SEQ ID NO: 353)
L-His Ser GIu GIy Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu GIu GIu GIu Leu VaI Lys Tyr Phe Leu GIn Trp Leu Lys Asn Ala GIy Pro Ser Lys Asn Asn He Ala GIu Ala
Lys-arachidoyl (SEQ ID NO: 354)
14. A pharmaceutical composition comprising a peptide as claimed in any one of claims 1 to 13 and one or more pharmaceutically acceptable carriers.
15. A pharmaceutical composition as claimed in claim 14 which is for peripheral administration.
16. A pharmaceutical composition as claimed in claim 14 or 15 which is for administration subcutaneously, intravenously, intramuscularly, intranasally, transdermally, transmucosally, orally, bucally, sublingually or via the lungs.
17. Use of a peptide as claimed in any one of claims 1 to 13 for the manufacture of a medicament for the prevention or treatment of obesity.
18. Use of a peptide as claimed in any one of claims 1 to 13 for the manufacture of a medicament for the prevention or treatment of diabetes or of a co-morbidity of obesity.
19. Use of a peptide as claimed in any of claims 1 to 13 for the manufacture of a medicament for reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject.
20. The use as claimed in claim any one of claims 17 to 19, wherein the peptide is administered peripherally.
21. The use as claimed in claim any one of claims 17 to 20, wherein the peptide is administered subcutaneously, intravenously, intramuscularly, intranasally, transdermally, transmucosally, orally, bucally, sublingually or via the lungs.
22. A peptide as claimed in any of claims 1 to 13 for use as a medicament.
23. A peptide as claimed in any of claims 1 to 13 for use as a medicament for the prevention or treatment of obesity.
24. A peptide as claimed in any of claims 1 to 13 for use as a medicament for the prevention or treatment of diabetes or of a co-morbidity of obesity.
25. A peptide as claimed in any of claims 1 to 13 for use as a medicament for reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject.
26. A peptide as claimed in any one of claims 22 to 25, wherein the peptide composition is administered peripherally.
27. A peptide as claimed in any one of claims 22 to 26, wherein the peptide is administered subcutaneously, intravenously, intramuscularly, intranasally, transdermally, transmucosally, orally, bucally, sublingually or via the lungs.
28. A method of treating or preventing obesity in a subj ect in need thereof comprising administering to the subject a peptide according to any of claims 1 to 13 or a pharmaceutical composition according to any of claims 14 to 16.
29. A method of treating or preventing diabetes or of a co-morbidity of obesity in a subject in need thereof comprising administering to the subject a peptide according to any of claims 1 to 13 or a pharmaceutical composition according to any of claims 14 to 16.
30. A method of reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject in need thereof comprising administering to the subject a peptide according to any of claims 1 to 13 or a pharmaceutical composition according to any of claims 14 to 16.
31. A method of causing weight loss or preventing weight gain for cosmetic purposes comprising administering to the subject a peptide according to any of claims 1 to 13 or a pharmaceutical composition according to claim 14 to 16.
32. A method as claimed in any of claims 28 to 31, wherein the subject is overweight.
33. A method as claimed in any of claims 28 to 32, wherein the subject is obese.
34. A method as claimed in any of claims 28 to 33, wherein the subject is diabetic.
35. The method of any of claims 28 to 34, wherein the peptide or pharmaceutical composition is administered peripherally.
36. The method of any of claims 28 to 35, wherein the peptide or pharmaceutical composition is administered subcutaneously, intravenously, intramuscularly, intranasally, transdermally, transmucosally, orally, bucally, sublingually or via the lungs.
PCT/GB2007/004779 2006-12-13 2007-12-13 Novel compounds and their effects on feeding behaviour WO2008071972A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002672406A CA2672406A1 (en) 2006-12-13 2007-12-13 Novel compounds and their effects on feeding behaviour
JP2009540858A JP5669395B2 (en) 2006-12-13 2007-12-13 New compounds and their effects on eating behavior
CN200780044820.9A CN101578107B (en) 2006-12-13 2007-12-13 Oxyntomodulin analogue and their effects on feeding behavior
BRPI0721093-0A BRPI0721093A2 (en) 2006-12-13 2007-12-13 COMPOUNDS AND THEIR EFFECTS ON FOOD BEHAVIOR
NZ578213A NZ578213A (en) 2006-12-13 2007-12-13 Appetite supressant peptides
MX2009006348A MX2009006348A (en) 2006-12-13 2007-12-13 Novel compounds and their effects on feeding behaviour.
AU2007331257A AU2007331257B2 (en) 2006-12-13 2007-12-13 Novel compounds and their effects on feeding behaviour
RU2009126634/04A RU2492183C2 (en) 2006-12-13 2007-12-13 Peptide, pharmaceutical composition (versions) and medication
UAA200907137A UA102370C2 (en) 2006-12-13 2007-12-13 Peptide, pharmaceutical composition and medicament comprising thereof, method for the treatment and/or prevention of diabetes and diseases associated with obesity, method for reduction in appetite, reduction in food intake or reduction of calorie intake
IL199247A IL199247A (en) 2006-12-13 2009-06-09 Oxyntomodulin derivative peptides, pharmaceutical compositions comprising the same and uses thereof for affecting feeding behavior

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB0624868.6A GB0624868D0 (en) 2006-12-13 2006-12-13 Novel compounds and their effects on feeding behaviour
GB0624868.6 2006-12-13
GB0625667.1 2006-12-21
GB0625667A GB0625667D0 (en) 2006-12-21 2006-12-21 Novel compounds and their effects on feeding behaviour
GB0700897.2 2007-01-17
GB0700897A GB0700897D0 (en) 2007-01-17 2007-01-17 Novel compounds and their effects on feeding behaviour

Publications (1)

Publication Number Publication Date
WO2008071972A1 true WO2008071972A1 (en) 2008-06-19

Family

ID=39106277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/004779 WO2008071972A1 (en) 2006-12-13 2007-12-13 Novel compounds and their effects on feeding behaviour

Country Status (22)

Country Link
US (3) US8101576B2 (en)
EP (2) EP2422808A3 (en)
JP (1) JP5669395B2 (en)
KR (1) KR20090098843A (en)
AR (1) AR064334A1 (en)
AU (1) AU2007331257B2 (en)
BR (1) BRPI0721093A2 (en)
CA (1) CA2672406A1 (en)
CO (1) CO6210830A2 (en)
CR (1) CR10923A (en)
EC (1) ECSP099513A (en)
GT (1) GT200900163A (en)
IL (1) IL199247A (en)
MX (1) MX2009006348A (en)
MY (1) MY152840A (en)
NI (1) NI200900116A (en)
NZ (1) NZ578213A (en)
RU (1) RU2492183C2 (en)
SG (1) SG177226A1 (en)
SV (1) SV2009003297A (en)
TW (1) TWI428346B (en)
WO (1) WO2008071972A1 (en)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666835B2 (en) 2001-09-07 2010-02-23 Imperial Innovations Limited Oxyntomodulin for preventing or treating excess weight
WO2010070252A1 (en) * 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
US7825091B2 (en) 2003-01-10 2010-11-02 Imperial Innovations Limited Modification of feeding behaviour
WO2011006497A1 (en) 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
WO2011088837A1 (en) 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
WO2011117416A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US8217001B2 (en) 2001-09-24 2012-07-10 Imperial Innovations Limited Modification of feeding behavior
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
US8367607B2 (en) 2009-12-22 2013-02-05 Eli Lilly And Company Oxyntomodulin peptide analogue
US8415296B2 (en) 2009-12-22 2013-04-09 Eli Lilly And Company Oxyntomodulin peptide analogue
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
US8642541B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
US8680049B2 (en) 2008-12-15 2014-03-25 Zealand Pharma A/S Glucagon analogues
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
WO2014056872A1 (en) 2012-10-09 2014-04-17 Sanofi Exendin-4 derivatives as dual glp1/glucagon agonists
WO2014147124A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
WO2014147129A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
WO2014161835A1 (en) 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
WO2015155141A1 (en) 2014-04-07 2015-10-15 Sanofi Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4
WO2015155139A1 (en) 2014-04-07 2015-10-15 Sanofi Exendin-4 derivatives as peptidic dual glp-1 / glucagon receptor agonists
WO2015155140A1 (en) 2014-04-07 2015-10-15 Sanofi Dual glp-1 / glucagon receptor agonists derived from exendin-4
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
US9181305B2 (en) 2012-06-14 2015-11-10 Sanofi Exendin-4 peptide analogues
US9180169B2 (en) 2012-09-17 2015-11-10 Zealand Pharma A/S Glucagon analogues
US9259477B2 (en) 2011-11-03 2016-02-16 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US9403894B2 (en) 2010-06-23 2016-08-02 Zealand Pharma A/S Glucagon analogues
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
WO2016193371A1 (en) 2015-06-05 2016-12-08 Sanofi Prodrugs comprising an glp-1/glucagon dual agonist linker hyaluronic acid conjugate
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US9522946B2 (en) 2011-06-10 2016-12-20 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US9724420B2 (en) 2012-11-06 2017-08-08 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region
US9731031B2 (en) 2011-06-17 2017-08-15 Hanmi Science Co., Ltd. Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
US9901621B2 (en) 2012-07-25 2018-02-27 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
EP3199546A4 (en) * 2014-09-23 2018-02-28 Jiang, Xianxing Oxyntomodulin analogue
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2018100174A1 (en) 2016-12-02 2018-06-07 Sanofi Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US10233230B2 (en) 2014-09-16 2019-03-19 Hanmi Pharm. Co., Ltd. Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
US10442847B2 (en) 2012-07-23 2019-10-15 Zealand Pharma A/S Glucagon analogues
US10513550B2 (en) 2014-12-30 2019-12-24 Hanmi Pharm Co., Ltd Glucagon derivatives
US10550168B2 (en) 2012-11-06 2020-02-04 Hanmi Pharm. Co., Ltd. Composition for treating diabetes or diabesity comprising oxyntomodulin analog
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2020125744A1 (en) 2018-12-21 2020-06-25 江苏恒瑞医药股份有限公司 Bispecific protein
US10905745B2 (en) 2016-12-09 2021-02-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DE602007009377D1 (en) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM
CN102274557B (en) 2006-08-09 2014-12-03 精达制药公司 Osmotic delivery systems and piston assemblies
DK2157967T3 (en) 2007-04-23 2013-04-08 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and applications thereof
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
LT2462246T (en) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
RU2670983C1 (en) * 2017-10-11 2018-10-29 Федеральное государственное бюджетное учреждение "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт" - ГосНИИгенетика) Using a polypeptide derived from human glucagon-like peptide 1 as a means to control body weight
JP2018090636A (en) * 2018-03-15 2018-06-14 インペリアル・イノベイションズ・リミテッド Novel compounds and their effects on feeding behavior

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022304A1 (en) * 2001-09-07 2003-03-20 Imperial College Innovations Limited Oxynthomodulin for preventing or treating excess weight
WO2004062685A2 (en) * 2003-01-10 2004-07-29 Imperial College Innovations Limited Modification of feeding behaviour and weight control by oxyntomodulin
WO2005035761A1 (en) * 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
WO2007056362A2 (en) * 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007100535A2 (en) * 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
WO2007146038A2 (en) * 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4223017A (en) 1975-04-15 1980-09-16 Burroughs Wellcome Co. Biologically active amides
US4175122A (en) 1975-04-15 1979-11-20 Burroughs Wellcome Co. Biologically active amides
GB1560933A (en) 1975-04-15 1980-02-13 Wellcome Found Biologically activy polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4220653A (en) 1979-01-24 1980-09-02 Vivino A Earl Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight
US4229389A (en) 1979-03-16 1980-10-21 Thompson Marine Corporation Gas diffuser, aerator, or sparger apparatus
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (en) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Means and product for the diagnosis and therapy of tumors and for the treatment of weaknesses in cellular and humoral immune defense
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4701441A (en) 1985-02-11 1987-10-20 University Of Florida Methods and compositions for stimulation of appetite
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
HU196755B (en) 1986-09-16 1989-01-30 Gyogyszerkutato Intezet Process for production of new substituated amilid derivatives and medical compositions containing them
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US5026685A (en) 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
DE68925966T2 (en) 1988-12-22 1996-08-29 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE9002278L (en) 1990-06-28 1991-12-29 Perstorp Ab APPLICATION OF INOSITOL TRISPHOSPHATE FOR THE PREPARATION OF A MEDICINE
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
US5175122A (en) * 1991-06-28 1992-12-29 Digital Equipment Corporation Planarization process for trench isolation in integrated circuit manufacture
CA2123108C (en) 1991-11-06 2003-03-25 Lisa Selbie Human neuropeptide y-y1 receptor
DK39892D0 (en) 1992-03-25 1992-03-25 Bernard Thorens PEPTIDE
JP3285583B2 (en) 1992-10-28 2002-05-27 株式会社クラレ Polyurethane and leather-like sheet using the polyurethane
JP2961045B2 (en) 1993-02-24 1999-10-12 日清製粉株式会社 Intestinal mucosa enhancement promoter
EP0692971A4 (en) 1993-03-29 1997-11-12 Univ Cincinnati Analogs of peptide yy and uses thereof
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5545549A (en) 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
WO1996014336A1 (en) 1994-11-07 1996-05-17 Kyowa Hakko Kogyo Co., Ltd. Novel oxyntomodulin
WO1996014331A1 (en) 1994-11-07 1996-05-17 Merck & Co., Inc. Modified neuropeptide y receptors
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5912227A (en) 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
DE69734168T2 (en) 1996-02-02 2006-01-19 Alza Corp., Mountain View Implantable system with delayed release of active ingredient
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US5919901A (en) 1996-04-08 1999-07-06 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
DE122009000079I2 (en) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle GLP-1 DERIVATIVES
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
JP2001504105A (en) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Use of GLP-1 peptide
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
DK0996459T3 (en) 1997-01-07 2006-01-16 Amylin Pharmaceuticals Inc Use of exendins and agonists thereof to reduce food intake
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
US5889016A (en) 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
DE04029691T1 (en) 1998-02-02 2007-11-08 Trustees Of Tufts College, Medford Use of dipetidylpeptidase inhibitors to regulate glucose metabolism
FR2774674B1 (en) 1998-02-10 2000-03-24 Atochem Elf Sa PROCESS FOR THE PREPARATION OF AN AQUEOUS SOLUTION OF HYDROGEN PEROXIDE DIRECTLY FROM HYDROGEN AND OXYGEN AND DEVICE FOR IMPLEMENTING SAME
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
FR2777283B1 (en) 1998-04-10 2000-11-24 Adir NOVEL GLUCAGON-PEPTIDE- 1 (7-37) ANALOGUE PEPTIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US6140354A (en) 1998-04-29 2000-10-31 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
DE69922676T2 (en) 1998-10-07 2005-12-15 Ortho-Mcneil Pharmaceutical, Inc. N-ARALKYLAMINOTETRALINES AS NEUROPEPTIDE Y-Y5 RECEPTOR LIGANDS
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
ES2353728T3 (en) 1999-02-10 2011-03-04 Curis, Inc. PEPTIDE YY (PYY) TO TREAT METABOLIC DISORDERS OF GLUCOSE.
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
WO2000068197A1 (en) 1999-05-05 2000-11-16 Ortho-Mcneil Pharmaceutical, Inc. 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ES2291210T3 (en) 1999-06-21 2008-03-01 Eli Lilly And Company SYNERGISTIC USE OF THIAZOLIDINDIONAS WITH PEPTIDO-1 TYPE GLUCAGONA AND ITS AGONISTS TO TREAT NON-INSULIN-DEPENDENT DIABETES.
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
ES2250170T3 (en) 1999-07-28 2006-04-16 Ortho-Mcneil Pharmaceutical, Inc. DERIVATIVES OF AMINAS AND AMIDAS USED AS BINDING FOR THE Y5 RECEPTOR OF THE NEUROPEPTIDE AND, USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS.
DE60025616T2 (en) 1999-08-25 2006-11-30 Banyu Pharmaceutical Co., Ltd. isoindole derivatives
WO2001013917A1 (en) 1999-08-26 2001-03-01 Bristol-Myers Squibb Company Npy antagonists: spiroisoquinolinone derivatives
AU6798000A (en) 1999-08-26 2001-03-19 Viropharma Incorporated Compounds, compositions and methods for treating influenza
IL148905A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Pfizer Inc Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
AU1269501A (en) 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
ES2311479T3 (en) 1999-11-26 2009-02-16 SHIONOGI &amp; CO., LTD. NPY-Y5 ANTAGONISTS.
JP2003519667A (en) 2000-01-10 2003-06-24 アミリン・ファーマシューティカルズ，インコーポレイテッド Use of exendin and its agonists for modulating triglyceride levels and treating dyslipidemia
WO2001066135A1 (en) 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
AU2001254686A1 (en) 2000-03-16 2001-09-24 Bayer Aktiengesellschaft Regulation of human neuropeptide y-like g protein-coupled receptor
IL142707A0 (en) 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
AU2001259056A1 (en) 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US6391881B2 (en) 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
KR100518046B1 (en) 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Treatment of acute coronary syndrome with glp-1
AU7327101A (en) 2000-07-06 2002-01-21 Metabasis Therapeutics Inc A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US20020156010A1 (en) 2000-11-20 2002-10-24 Lustig Robert H. Method of treating obesity in adult patients exhibiting primary insulin hypersecretion
BR0116024A (en) * 2000-12-07 2005-12-13 Lilly Co Eli Heterologous Fusion Protein and Use thereof
MXPA03005388A (en) 2000-12-14 2003-09-25 Amylin Pharmaceuticals Inc Peptide yy and peptide yy agonists for treatment of metabolic disorders.
WO2002066479A1 (en) 2001-02-23 2002-08-29 Banyu Pharmaceutical Co.,Ltd. Novel isoindole derivatives
WO2002067918A1 (en) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Novel diallylmethylamine derivative
WO2003009845A1 (en) 2001-07-26 2003-02-06 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
DK1499277T3 (en) 2001-09-24 2009-05-11 Imp Innovations Ltd PYY-36 for reducing or preventing obesity
EP2329839B1 (en) 2002-01-10 2015-09-16 Imperial Innovations Limited Modification of feeding behavior by GLP-1 and PYY
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
CN1220702C (en) 2003-07-30 2005-09-28 北京中科亚光生物科技有限公司 Insulinotropic peptide and its use
KR20070039911A (en) 2004-06-01 2007-04-13 도만티스 리미티드 Bispecific fusion antibodies with enhanced serum half-life
PA8660701A1 (en) 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
BRPI0612069A2 (en) 2005-06-13 2009-01-20 Imp Innovations Ltd compounds and their effects on feeding behavior
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022304A1 (en) * 2001-09-07 2003-03-20 Imperial College Innovations Limited Oxynthomodulin for preventing or treating excess weight
WO2004062685A2 (en) * 2003-01-10 2004-07-29 Imperial College Innovations Limited Modification of feeding behaviour and weight control by oxyntomodulin
WO2005035761A1 (en) * 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
WO2007056362A2 (en) * 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007100535A2 (en) * 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
WO2007146038A2 (en) * 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 9 September 2004 (2004-09-09), XP002471184, retrieved from CAA27627 Database accession no. CAA27627 *

Cited By (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666835B2 (en) 2001-09-07 2010-02-23 Imperial Innovations Limited Oxyntomodulin for preventing or treating excess weight
US8217001B2 (en) 2001-09-24 2012-07-10 Imperial Innovations Limited Modification of feeding behavior
US7825091B2 (en) 2003-01-10 2010-11-02 Imperial Innovations Limited Modification of feeding behaviour
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
EA020520B1 (en) * 2008-12-15 2014-11-28 Зилэнд Фарма А/С Glucagon analogues
WO2010070252A1 (en) * 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
US8680049B2 (en) 2008-12-15 2014-03-25 Zealand Pharma A/S Glucagon analogues
US8642541B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
WO2011006497A1 (en) 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
US10004786B2 (en) 2009-07-13 2018-06-26 Zealand Pharma A/S Acylated glucagon analogues
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
US8367607B2 (en) 2009-12-22 2013-02-05 Eli Lilly And Company Oxyntomodulin peptide analogue
US8415296B2 (en) 2009-12-22 2013-04-09 Eli Lilly And Company Oxyntomodulin peptide analogue
WO2011088837A1 (en) 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
JP2013523619A (en) * 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス New glucagon analog
RU2559320C2 (en) * 2010-03-26 2015-08-10 Ново Нордиск А/С Novel glucagon analogues
WO2011117415A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
AU2011231503C1 (en) * 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
JP2016183192A (en) * 2010-03-26 2016-10-20 ノヴォ ノルディスク アー／エス Novel glucagon analogs
AU2011231503B2 (en) * 2010-03-26 2014-11-06 Novo Nordisk A/S Novel glucagon analogues
WO2011117416A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
US9649362B2 (en) 2010-04-27 2017-05-16 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
US10406207B2 (en) 2010-04-27 2019-09-10 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
US9403894B2 (en) 2010-06-23 2016-08-02 Zealand Pharma A/S Glucagon analogues
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
US9522946B2 (en) 2011-06-10 2016-12-20 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US9527898B2 (en) 2011-06-10 2016-12-27 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US9765131B2 (en) 2011-06-10 2017-09-19 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US10442848B2 (en) 2011-06-10 2019-10-15 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US10363320B2 (en) 2011-06-17 2019-07-30 Hanmi Science Co., Ltd. Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US11872283B2 (en) 2011-06-17 2024-01-16 Hanmi Science Co., Ltd Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US9731031B2 (en) 2011-06-17 2017-08-15 Hanmi Science Co., Ltd. Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US9486505B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
US9861706B2 (en) 2011-11-03 2018-01-09 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US9259477B2 (en) 2011-11-03 2016-02-16 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US9181305B2 (en) 2012-06-14 2015-11-10 Sanofi Exendin-4 peptide analogues
US11795204B2 (en) 2012-07-23 2023-10-24 Zealand Pharma A/S Glucagon analogues
US10442847B2 (en) 2012-07-23 2019-10-15 Zealand Pharma A/S Glucagon analogues
US10493132B2 (en) 2012-07-25 2019-12-03 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
US9901621B2 (en) 2012-07-25 2018-02-27 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
US10253081B2 (en) 2012-09-17 2019-04-09 Zealand Pharma A/S Glucagon analogues
US9975939B2 (en) 2012-09-17 2018-05-22 Zealand Pharma A/S Glucagon analogues
US9180169B2 (en) 2012-09-17 2015-11-10 Zealand Pharma A/S Glucagon analogues
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
US10758592B2 (en) 2012-10-09 2020-09-01 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
WO2014056872A1 (en) 2012-10-09 2014-04-17 Sanofi Exendin-4 derivatives as dual glp1/glucagon agonists
US9365632B2 (en) 2012-10-09 2016-06-14 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
US9724420B2 (en) 2012-11-06 2017-08-08 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region
US10550168B2 (en) 2012-11-06 2020-02-04 Hanmi Pharm. Co., Ltd. Composition for treating diabetes or diabesity comprising oxyntomodulin analog
US11071785B2 (en) 2012-11-06 2021-07-27 Hanmi Pharm. Co., Ltd. Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin Fc region
US10279041B2 (en) 2012-11-06 2019-05-07 Hanmi Pharm Co. Ltd. Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
US9745360B2 (en) 2012-12-21 2017-08-29 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US10253079B2 (en) 2012-12-21 2019-04-09 Sanofi Functionalized Exendin-4 derivatives
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
WO2014147124A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
WO2014147129A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
WO2014161835A1 (en) 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9751927B2 (en) 2013-04-18 2017-09-05 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US11884713B2 (en) 2013-10-17 2024-01-30 Zealand Pharma A/S Acylated glucagon analogues
US11034747B2 (en) 2013-10-17 2021-06-15 Zealand Pharma A/S Glucagon analogues and methods of use
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
US10457714B2 (en) 2013-10-17 2019-10-29 Zealand Pharma A/S Acylated glucagon analogues
US11091528B2 (en) 2013-10-17 2021-08-17 Zealand Pharma A/S Acylated glucagon analogues
US11111285B2 (en) 2013-11-06 2021-09-07 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US11008375B2 (en) 2013-11-06 2021-05-18 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
WO2015155140A1 (en) 2014-04-07 2015-10-15 Sanofi Dual glp-1 / glucagon receptor agonists derived from exendin-4
WO2015155139A1 (en) 2014-04-07 2015-10-15 Sanofi Exendin-4 derivatives as peptidic dual glp-1 / glucagon receptor agonists
WO2015155141A1 (en) 2014-04-07 2015-10-15 Sanofi Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10233230B2 (en) 2014-09-16 2019-03-19 Hanmi Pharm. Co., Ltd. Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
US10435459B2 (en) 2014-09-16 2019-10-08 Hanmi Pharm. Co., Ltd. Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
EP3199546A4 (en) * 2014-09-23 2018-02-28 Jiang, Xianxing Oxyntomodulin analogue
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
US11814417B2 (en) 2014-10-29 2023-11-14 Zealand Pharma A/S GIP agonist compounds and methods
US11001619B2 (en) 2014-10-29 2021-05-11 Zealand Pharma A/S GIP agonist compounds and methods
US10513550B2 (en) 2014-12-30 2019-12-24 Hanmi Pharm Co., Ltd Glucagon derivatives
US11254724B2 (en) 2014-12-30 2022-02-22 Hanmi Pharm. Co., Ltd. Glucagon derivatives
US11274136B2 (en) 2015-04-16 2022-03-15 Zealand Pharma A/S Acylated glucagon analogue
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
US10806797B2 (en) 2015-06-05 2020-10-20 Sanofi Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
WO2016193371A1 (en) 2015-06-05 2016-12-08 Sanofi Prodrugs comprising an glp-1/glucagon dual agonist linker hyaluronic acid conjugate
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US11141489B2 (en) 2016-12-02 2021-10-12 Sanofi Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid
WO2018100174A1 (en) 2016-12-02 2018-06-07 Sanofi Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
US10792367B2 (en) 2016-12-02 2020-10-06 Sanofi Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid
US11395847B2 (en) 2016-12-09 2022-07-26 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
US10905745B2 (en) 2016-12-09 2021-02-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
WO2020125744A1 (en) 2018-12-21 2020-06-25 江苏恒瑞医药股份有限公司 Bispecific protein

Also Published As

Publication number Publication date
EP2422808A2 (en) 2012-02-29
AR064334A1 (en) 2009-04-01
BRPI0721093A2 (en) 2014-02-11
CO6210830A2 (en) 2010-10-20
EP1985304A2 (en) 2008-10-29
CR10923A (en) 2009-11-09
AU2007331257A1 (en) 2008-06-19
TWI428346B (en) 2014-03-01
MX2009006348A (en) 2009-06-30
NZ578213A (en) 2012-04-27
EP1985304A3 (en) 2009-01-14
RU2492183C2 (en) 2013-09-10
JP2010513256A (en) 2010-04-30
MY152840A (en) 2014-11-28
IL199247A (en) 2014-04-30
US20130089545A1 (en) 2013-04-11
SG177226A1 (en) 2012-01-30
EP2422808A3 (en) 2012-06-13
AU2007331257B2 (en) 2013-06-27
NI200900116A (en) 2010-06-22
CA2672406A1 (en) 2008-06-19
KR20090098843A (en) 2009-09-17
US20090181885A1 (en) 2009-07-16
US8101576B2 (en) 2012-01-24
GT200900163A (en) 2011-11-22
ECSP099513A (en) 2009-08-28
SV2009003297A (en) 2010-02-17
US20150018289A1 (en) 2015-01-15
JP5669395B2 (en) 2015-02-12
TW200827370A (en) 2008-07-01
RU2009126634A (en) 2011-01-20

Similar Documents

Publication Publication Date Title
AU2007331257B2 (en) Novel compounds and their effects on feeding behaviour
AU2006258841B2 (en) Oxyntomodulin analogues and their effects on feeding behaviour
US20150011467A1 (en) Oxyntomodulin analogues and their effects on feeding behaviour
EP1871794B1 (en) Modified pyy(3-36) peptides and their effects on feeding behavior
AU2008273941B2 (en) Human pancreatic polypeptide (HPP) analogues and their effects on feeding behaviour
AU2011210165B2 (en) Novel compounds and their effects on feeding behaviour
CA2825611A1 (en) Novel compounds and their effects on feeding behaviour
AU2018379704B2 (en) Analogues of PYY

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780044820.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07848523

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007331257

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3444/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12009501159

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2007331257

Country of ref document: AU

Date of ref document: 20071213

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2672406

Country of ref document: CA

Ref document number: 2009060888

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 2009540858

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/006348

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 09062877

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020097013317

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 578213

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2009126634

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A200907137

Country of ref document: UA

Ref document number: CR2009-010923

Country of ref document: CR

122 Ep: pct application non-entry in european phase

Ref document number: 07848523

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: PI0721093

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090612